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Psoriasis is a common, chronic inflammatory skin disease with associated 
autoantigens, autoantibodies, local and systemic inflammation, and systemic 
comorbidities, such as cardiovascular disease and metabolic syndrome. Patients with 
severe disease often need biological treatment targeting the cytokines tumour necrosis 
factor (TNF), interleukin (IL)-12/23 or IL-17. The lack of precise laboratory analyses 
to aid selection of drug and monitor treatment effect along with adverse events and 
loss of treatment efficacy in a significant proportion of patients treated with 
biological drugs generate a need for robust assays used for monitoring and predicting 
treatment outcome. 
The overall aim of this thesis was to analyse peripheral blood immune cells during 
active inflammation and treatment with biological drugs and to identify disease-
specific immune profiles and biomarkers. In study I and II phospho-specific flow 
cytometry and mass cytometry were used, respectively, to study phenotypes and 
function of peripheral blood mononuclear cells (PBMCs) from healthy controls and 
patients on steady treatment with infliximab (IFX), a TNF inhibitor, and to examine 
the impact of switching from originator IFX to biosimilar CT-P13. In study III, mass 
cytometry was exploited to analyse PBMCs from healthy controls and patients 
starting biological treatment with emphasis on the T cell lineage and its intracellular 
signalling. In all studies, clinical and standard laboratory parameters were 
incorporated in the analyses. 
In study I and II, increased phosphorylation levels in PBMCs were detected in 
psoriasis patients compared to healthy controls. The phosphorylation levels decreased 
during continued treatment, without completely normalising, despite clinical 
remission. Specifically, in study II, psoriasis patients had higher expression of CD38 
in NK and CD4+ T effector memory cells. In neither study I nor II any obvious 
differences were seen comparing originator IFX and CT-P13, with respect to cell 
frequencies, phosphorylation levels, clinical or laboratory data.  
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Study III revealed a shift from helper T (Th)1 to Th2 cells, a transition from 
naïve/effector to memory predominance, reduction of circulating Th17, Th22, Th9 
and CD8+ T cells and enhancement of inhibitory programmed cell death protein 1 
(PD-1) expression on T cells after onset of treatment with a TNF-, IL-12/23- or IL-17 
inhibitor. Also, the monocyte compartment showed changes favouring reduced 
cardiovascular risk after treatment onset. Intracellular phosphorylation was higher in 
psoriasis patients compared to healthy controls and non-responders to treatment 
compared to responders.  
In conclusion, multiple aberrancies were seen in cellular frequencies in patients 
before treatment with biological drugs. In both untreated patients and patients on 
originator IFX and biosimilar CT-P13, our findings support a more activated state of 
PBMCs. These findings provide evidence for an ongoing systemic inflammation both 
with and without biological treatment, implying an increased risk of comorbidities, 
such as cardiovascular disease. Further research will help to shed light on the role of 
PBMCs as potential reporters used for personalised treatment both with regards to the 




 ADA    Anti-drug antibodies 
APC   Antigen Presenting Cell  
BMI   Body Mass Index 
CCL20   Chemokine (C-C motif) Ligand 20  
CCR4 (6, 10) C-C Chemokine Receptor type 4 (6, 10) 
CD    Cluster of Differentiation 
CRP   C-Reactive Protein 
CT    Computed Tomography 
CTP-13  Infliximab biosimilar 
CVD   Cardiovascular Disease 
CXCL   Chemokine (C-X-C motif) Ligand 
CXCR3  C-X-C Chemokine Receptor type 3 
DC    Dendritic Cell 
DLQI   Dermatological Life Quality Index 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
e.g.    exempli gratia 
ERK   Extracellular Signal-Regulated Kinases 
FC    Fold Change 
FlowSOM  Flow Self-Organising Maps 
HLA   Human Leukocyte Antigen 
i.e.    id est 
IFN   Interferon 
IFX   Infliximab 
IκB    Inhibitor of κB 
IKK   Inhibitor of κB kinase 
IL    Interleukin 
JAK   Janus Kinase 
LL37   Cathelicidin 
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MAPK   Mitogen-Activated Protein Kinase 
MC   Monocyte 
mDC   Myeloid Dendritic Cell 
MFI   Median Fluorescence Intensity 
MSI   Median Signal Intensity 
MTX   Methotrexate 
NEMO   NF-κB essential modulator 
NET   Neutrophil Extracellular Trap 
NF-κB   Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NK    Natural Killer 
PASI   Psoriasis Area and Severity Index 
PBMC   Peripheral Blood Mononuclear Cell 
PD-1   Programmed cell death protein 1 
pDC   Plasmacytoid Dendritic Cell 
PET   Positron Emission Tomography 
PMT   Photomultiplier Tube 
RNA   Ribonucleic Acid 
STAT   Signal Transducer and Activator of Transcription 
Tc    Cytotoxic T cell 
TCM   Central memory T cell 
TEM   Effector memory T cell 
TEMRA   Terminally differentiated effector memory T cell 
Th    Helper T cell 
TLR   Toll-Like Receptor 
TNF   Tumour Necrosis Factor 
Treg   Regulatory T cell 
Trm   Tissue-resident memory cell 
TYK   Tyrosine Kinase 





1.1 Background psoriasis 
Psoriasis is a common immune-mediated disease, which manifests in the skin, joints, 
or both, in genetically predisposed individuals.1 
1.1.1 Epidemiology 
The prevalence of psoriasis in adults ranges from 0,5% to 11,4% in different studies, 
is equally prevalent in men and women and varies between different ethnicities.1-5 
Psoriasis can occur at any age, but there are two incidence peaks for psoriasis debut. 
Early debut, age 16-22, is called type I psoriasis, and late debut, age 57-66, is called 
type II psoriasis.1,6-8 The early form is often more severe than the late form, and a 
family history with psoriasis in first-degree family members is more common.6  
1.1.2 Classification 
Psoriasis is a heterogenous disease, where several different forms have been 
described, but the most common subtypes include plaque, guttate, erythrodermic, and 
pustular psoriasis.1,9 Psoriasis vulgaris, or chronic plaque psoriasis, is the most 
common subtype. About 90% of psoriasis cases are of the chronic plaque type, which 
is characterised by sharply demarcated, symmetrically distributed, erythematous 
lesions with loosely adherent silvery-white scales (Figure 1A-C).1,9 Typical locations 
include the extensor surfaces on elbows and knees, peri-umbilical, peri-anal, lumbar 
and retro-auricular regions, and scalp.1,10-12 It can, however, affect any skin site and 
the disease can become generalised over time.1,12 Inverse psoriasis, a variant of 
psoriasis vulgaris, occurs in flexural and intertriginous areas, and lesions are usually 
deprived of scales due to friction and moisture.1,10-12 Guttate psoriasis is an acute 
eruption of small papules, typically appearing over a period of one month, persisting 
for one month and resolving over the third month.12 It is the most common form of 
psoriasis in children and young adults, and is often preceded by a streptococcal throat 
infection.11,12 One third of children with guttate psoriasis develop plaque psoriasis 
later in life.1,11,13 Pustular psoriasis is characterised by white coalescing pustules and 
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can be either localised or generalised.1 Erythroderma is characterised by widespread 
cutaneous erythema covering > 90% of the body surface.12 Both erythroderma and 
generalised pustular psoriasis are life-threatening diseases, as a result of 
compromised cutaneous functions. Due to loss of fluid, electrolytes, proteins, iron 
and a reduced temperature control and cutaneous barrier against microorganisms, 
fever or hypothermia, hypovolemia, electrolyte disturbances, hypoalbuminemia, 
anaemia, and sepsis can occur.9 Erythroderma and generalised pustular psoriasis are 
often preceded by psoriasis vulgaris, but may arise de novo.1,12 A typical precipitating 
factor is withdrawal of systemic glucocorticoids.12  
1.1.3 Histology and inflammatory infiltrate 
In psoriatic lesions the epidermis is thickened due to increased keratinocyte 
proliferation. Epidermal acanthosis, hyperkeratosis and elongation of rete ridges is 
typical. In the dermis, dilated blood vessels reach the tip of dermal papillae.1,14,15 A 
mixed inflammatory infiltrate consisting of epidermal and dermal T cells and an 
increased number of macrophages, mast cells and neutrophils in the epidermis is 
often seen. Accumulation of inflammatory cells within the epidermis and formation 
of micro-abscesses is also typical (Figure 1 D-G).14,16,17 
A study of human skin grafted on immunodeficient mice revealed that progression 
towards psoriasiform changes only happened when T cells had entered the epidermis, 





Figure 1. Clinical and Histologic Features of Psoriasis. Erythematous, scaly, sharply demarcated 
plaques in different sizes and shapes are hallmarks of psoriasis. Although there are predilection sites 
such as the elbows, knees, and the sacral region, lesions may cover the entirety of the skin (Panels A 
and C). Concurrent psoriatic arthritis often affects multiple aspects of the interphalangeal joints of the 
hand (Panel B). The nails are frequently affected, with nail dystrophy and psoriatic lesions of the nail 
bed. The histopathological picture (Panel D, hematoxylin and eosin) is characterised by thickening of 
the epidermis, parakeratosis, elongated rete ridges, and a mixed cellular infiltrate. CD3+ T cells 
(Panel E, 3,3′-diaminobenzidine and hematoxylin) and CD8+ T cells (Panel F, 3,3′-diaminobenzidine 
and hematoxylin) are detected around capillaries of the dermis and in the epidermis. CD11c+ 
dendritic cells (Panel G, 3,3′-diaminobenzidine and hematoxylin) are detected mainly within the 
upper part of the dermis. (Clinical photographs courtesy of St. John's Institute of Dermatology.) 
Reproduced with permission from Nestle et al., 2009,15 Copyright Massachusetts Medical Society. 
 
1.1.4 Assessment of disease severity 
Psoriasis is classified either as mild, moderate, or severe by evaluating surface area 
affected and severity of the lesions. Psoriasis area and severity index (PASI) is a 
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validated tool that combines the area affected and the severity of the lesions into a 
single score ranging from 0 to 72.19,20 Scores above 10 are usually considered severe 
disease.21 Response to treatment is often presented as a percentage reduction in PASI, 
e.g. PASI75.22 
Assessment of life quality by Dermatology Life Quality Index (DLQI) is 
recommended because psoriasis may result in functional, psychological, and social 
morbidity, even in people with minimal involvement (less than the equivalent of three 
palm areas).23 DLQI consists of 10 standardised questions about the patients' 
impression of how the disease has affected their quality of life over the last week.24 
Moreover, considering prior treatment response, involvement of special areas (face, 
scalp, palms, soles, and genitals) and presence of comorbidities is also recommended 
to avoid underestimation of disease severity.23,25,26 Finally, Physician's global 
assessment, Body surface area and Nail Psoriasis Severity Index can also be used to 
assess disease severity.22  
1.1.5 Genetics 
The genetic nature of psoriasis has for long been appreciated, with a concordance rate 
of approximately 70% and 20% in monozygotic and dizygotic twins, respectively.14  
The most predominant susceptibility allele for psoriasis, the human leukocyte antigen 
(HLA) susceptibility locus HLA-C*06:02, accounts for up to 50% of disease 
heritability and is strongly associated with early onset and more severe disease.27-29 
Moreover, being located in the HLA class I region, which is responsible for antigen 
presentation to CD8+ T cells, this locus links psoriasis genetics with proposed 
autoantigens.14,30 
Two highly penetrant gene mutations have been reported to cause psoriasis, namely 
IL36RN and CARD14. Both lead to increased activity of Nuclear Factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and excessive production of NF-κB-
regulated cytokines.14,31,32 Otherwise, psoriasis is a complex multifactorial disease 
with many genes contributing to disease risk, where at least 12 major psoriasis 
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susceptibility loci and near 40 single nucleotide polymorphisms have been 
identified,1,14,33 including genes related to antigen presentation, keratinocyte 
proliferation and immune regulation.34 
1.1.6 Triggering factors 
In predisposed individuals, several stimuli can trigger psoriasis. Psoriatic lesions can 
appear in areas of the skin that have recently been injured, for example after mild 
traumas such as scratching, sunburn, or chemical irritants.1 Infections can trigger or 
exacerbate psoriasis. Infection with β-haemolytic streptococci is the prime example 
of this. It is thought to trigger guttate psoriasis35 and exacerbations of plaque 
psoriasis36 via molecular mimicry where lymphocytes reactive to the M-protein on 
group A β-haemolytic streptococci recognise human keratin 17, resulting in keratin 
17-reactive CD8+ T cells that elicit significant interferon (IFN)-γ responses.37 
Moreover, tonsillectomy in patients with recurring tonsilitis can improve psoriasis.38 
Also, systemic drugs such as β-blockers, lithium, quinolinic anti-malarials and non-
steroidal anti-inflammatory drugs can induce or worsen psoriasis,1,39 and withdrawal 
of systemic glucocorticoids can induce severe exacerbations, including generalised 
pustular psoriasis.39,40 Finally, stress is a known trigger of psoriasis, and tobacco 
smoking and obesity increase the risk of psoriasis onset.41,42 
1.2 Immunopathogenesis and inflammation in psoriasis 
In genetically susceptible individuals, autoantigens can stimulate the innate and 
adaptive immune system. In response to the cytokine milieu, mediated by immune 
cells, keratinocytes proliferate and produce antimicrobial peptides and chemokines, 
leading to further recruitment of cytokine-producing immune cells which amplifies 
the pathologic state.  
1.2.1 Initiation of psoriatic lesions 
In general, naïve T cells require presentation of an antigen by a professional antigen-
presenting cell (APC), such as dendritic cells (DC), to become activated.43 Thus, 
there must be an upstream initiating event which leads to presentation of autoantigens 
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to naive T cells. In the epidermis several autoantigens have been identified as objects 
of T cell-reactivity including cathelicidin (LL37),44 disintegrin‐like and 
metalloprotease domain containing thrombospondin type 1 motif‐like 5 
(ADAMTSL5),45 keratin 17,46,47 and phospholipase A2 group IVD (PLA2G4D) 
(Figure 2).48 The cationic antimicrobial peptide LL37 is the most studied autoantigen 
in psoriasis. In response to skin injury or infection, LL37 is produced by several 
immune cells and keratinocytes.44,49 Due to its positive charge, LL37 forms 
complexes with negatively charged DNA and RNA, released from damaged cells, 
e.g. neutrophil extracellular traps (NET).16,50,51 LL37 bound to DNA or RNA 
activates LL37-specific plasmacytoid DCs (pDCs) via toll-like receptor (TLR)9 and 
TLR7, respectively.50,52 Activated pDCs produce IFN-α which activates myeloid DCs 
(mDCs).52,53 Further, a recent study found that RNA-bound LL37 triggered TLR8-
mediated cytokine and NET release by polymorphonuclear neutrophils (PMNs). This 
uncovers PMNs capability of self-maintaining a vicious cycle through both sensing 
the inflammatory ligand RNA-LL37 and releasing RNA-LL37 and DNA-LL37 
complexes.51 RNA-bound LL37 also activates mDCs by binding TLR7/8.52 Hence, 
mDCs can be activated by both type 1 IFNs and RNA-LL37, driving T cell activation 
and the production of cytokines found in psoriasis. 
1.2.2 Immune cell interplay and cytokines 
Psoriasis lesions contain CD4+ T cells that produce IFN-γ, interleukin (IL)-17, and 
IL-22, labeled as Th1, Th17, and Th22, respectively. There are also CD8+ T cell 
populations producing the same range of cytokines, termed cytotoxic T cells (Tc)1, 
Tc17, and Tc22, respectively.14 Activated DCs facilitate the differentiation of naïve 
CD4+ T cells into effector cells in the lymph nodes.54-56 Upon stimulation with IL-12 
and IFN-γ, naïve CD4+ T cells will differentiate to Th1 cells.57 Stimulation with IL-
23, IL-1β and IL-6 will generally promote Th17 differentiation,58 whilst the 
combination of tumour necrosis factor (TNF) and IL-6 drives the differentiation of 
Th22 cells.59 Lastly, Transforming Growth Factor-β (TGF-β), in concert with IL-2, is 
also involved in the differentiation of regulatory T cells (Tregs), which are important 
suppressors of the inflammatory response, and thus important for stopping 
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inflammation.60 Cytokines produced by Th1, Th17 and Th22 are key factors in the 
pathogenesis of psoriasis.15,55,61-63 
 
 
Figure 2. Autoantigens and their potential role in the development of psoriatic skin.  
As a result of environmental stimuli (e.g., infection or skin trauma), damaged keratinocytes release 
LL‐37 in genetically susceptible individuals. The antimicrobial peptide LL‐37 forms complexes with 
self‐DNA/RNA originating from NETs. LL‐37‐DNA complexes initiate IFN‐α release from pDCs, 
which in turn activates cDCs. Activation of cDC triggers the expression of TNF, IL‐23 and IL‐12 
inducing Th17, Th22 and Th1 cell subsets, resulting in the production of pro‐inflammatory cytokines. 
Alternatively, ADAMTSL5 in melanocytes results in the activation of intraepidermal CD8+ CTL and 
increased amounts of IFN‐γ and IL‐17. Moreover, CTL reactive to the surface M protein from 
streptococci may recognise keratin 17 via molecular mimicry resulting in IFN‐γ production. Finally, 
psoriatic mast cells are a major source of PLA2G4D that generates neolipid antigens recognized by 
Langerhans cells, which in response activate lipid‐specific T cells. ADAMTSL5 disintegrin‐like and 
metalloprotease domain containing thrombospondin type 1 motif‐like 5, cDC conventional dendritic 
cell, CTL cytotoxic T cell, IL interleukin, IFN interferon, KC keratinocyte, LC Langerhans cell, NET 
neutrophil extracellular trap, pDC plasmacytoid dendritic cell, PLA2G4D phospholipase A2 group 
IVD, Th T helper lymphocyte, TNF tumour necrosis factor. Figure and text adapted from ten Bergen 
et al., 2020.64 Reprinted with permission from John Wiley and Sons. 
 
The local milieu of cytokines, chemokines and antimicrobial peptides favor 
hyperproliferation,65 LL-37 production,66 TLR9 responsiveness67 and production of 
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cytokines68,69 and chemokines70,71 in keratinocytes, along with attraction of immune 
cells, including T cells, DCs, neutrophils and monocytes.15,51,72 The importance of 
recruitment of immune cells from the circulation is demonstrated by the effect of 
efalizumab, which blocks the α subunit of CD11a, inhibiting the binding of T 
lymphocytes to endothelial cells, and their movement from the circulation into dermal 
and epidermal tissues.73 The continuous activation of DCs, T cells and keratinocytes, 
which promotes further recruitment of immune cells, and thereby enhancing the 
inflammatory response within the psoriatic lesion, results in a self-amplifying 
feedforward loop.14,16 Importantly, other cell types than CD4+ and CD8+ T cells can 
produce cytokines promoting the forementioned local effects, including neutrophils, 
macrophages, innate lymphoid cells, natural killer (NK) cells and γδ T cells,74-79 and 
are, thus, likely to contribute to the chronic inflammation in psoriasis.80 In addition, 
Treg function has been reported to be impaired during psoriatic inflammation.17,81 
Usually, Tregs maintain immune tolerance by releasing inhibitory cytokines, 
inducing apoptosis and by consumption of IL-2.82,83 However, in psoriasis they are 
dysfunctional, with reduced suppressive capacity.14,84,85 Pro-inflammatory cytokines, 
such as IL-6 and IL-17, which are abundant in psoriatic lesions, have been reported to 
suppress Treg function, and provide a plausible explanation of the suppressed Treg 
function and increased proliferation of pathogenic T cells in psoriatic lesions.17,84,86,87 
Psoriasis lesions often recur in the same locations and regrow to their prior size once 
therapy is stopped. A possible mechanism is that some T cells progress toward 
differentiation into tissue-resident memory CD8+ T (Trm) cells after recognition of 
autoantigens.88,89 In resolved psoriasis, Trm cells have been detected and are thought 
to constitute a site-specific disease memory, together with epidermal Tc17 and Th22 
cells.55,62,88,90-93 In addition of innate immune mediators, keratinocytes may act as 
non-professional APCs and induce immune responses in antigen-experienced Th and 
Tc memory cells, leading to functional responses like cytokine production or 
cytotoxic effects.94,95 
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1.2.3 Systemic inflammation 
As psoriasis progresses, serum levels of multiple pro-inflammatory cytokines are 
increased compared to healthy controls, including TNF, IFN-γ, IL-6, IL-8, IL-12, IL-
17A and IL-1896-99 Furthermore, increased frequencies of circulating Th17 cells, and 
elevated levels of C-reactive protein (CRP) have been reported in psoriasis 
patients.100,14 Studies using 18F-fluorodeoxyglucose positron emission 
tomography/computed tomography (FDG PET/CT) on patients with moderate-to-
severe psoriasis demonstrate subclinical inflammation in the liver, joints and tendons, 
and significantly increased global arterial and subcutaneous inflammation,101,102 
emphasising a potential benefit of systemic treatment in this patient group.26 Also, 
patients with mild psoriasis have been found to have subclinical inflammation in the 
aorta.103 After a study of the skin transcriptome and serum protein measurements in 
85 patients with moderate-to-severe psoriasis compared with serum proteomics in 
healthy controls, a model for systemic inflammation in psoriasis was created, which 
proposed that a subset of inflammatory products is produced at high levels in lesional 
psoriatic skin and diffuses into the systemic circulation.14,97 Increased understanding 
of the roles of these pathogenic molecular pathways has led to an appreciation of the 
systemic nature of psoriasis and given rise to biological drugs that target cytokines 
involved in the pathogenesis of the disease.99 
1.3 Comorbidities in psoriasis 
1.3.1 Cardiovascular disease and metabolic syndrome 
Psoriasis has for long been thought to be a risk factor of cardiovascular disease 
(CVD), and many epidemiological studies substantiate this,104-110 although conflicting 
findings exist.111,112 Large meta-analyses and prospective cohort-studies showing 
increased risk of coronary artery disease, myocardial infarction and stroke in patients 
with psoriasis, where the risk correlates with disease severity and duration, strengthen 
the hypothesis of psoriasis being an independent risk factor for CVD.105,110,113-115 
However, the causes of this increased risk are complex and not fully elucidated.113 
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Both psoriasis and metabolic syndrome are associated with CVD. Psoriasis patients 
are at increased risk of developing metabolic syndrome.116,117 Furthermore, increasing 
severity of psoriasis correlates with increasing frequency of dyslipidaemia.118,119 In 
addition, smoking is a common risk factor for both CVD and psoriasis.120 Thus, both 
smoking and metabolic syndrome are important confounding factors. Patients with 
severe psoriasis have been estimated to have an additional risk of 6,2% on 10-year 
incidence of major adverse cardiovascular events, compared with the general 
population, after adjusting for age, gender, diabetes, hypertension, smoking and 
hyperlipidaemia.121 Moreover, studies that have utilised CT and PET/CT have found 
increased coronary artery and aortic inflammation, respectively, in psoriasis patients 
compared with healthy controls after controlling for confounding factors.101,102,122 
A direct link between psoriasis and CVD is increasingly accepted as more knowledge 
has been gained regarding the immunopathogenesis of the two diseases.80 Lesional 
psoriatic skin and atherosclerosis exhibit significant overlap of their transcriptomes, 
with IFN-γ and TNF being inflammatory mediators shared between the two disease 
processes. Moreover, IFN-γ and TNF, which are elevated in sera of psoriasis patients, 
synergistically increase the inflammatory responses in endothelial cells and 
atherosclerotic tissue, and may therefore provide a link between the two diseases.123 
Because of the link between IL-17A and neutrophil infiltration in atherosclerotic 
plaques and its importance in the pathogenesis of psoriasis the IL-17A/neutrophil axis 
has been suggested to take part in the atherogenesis associated with psoriasis.124,125 
Studies of IL-17A in atherosclerosis are contradictory,126 and although it seems to be 
mostly pro-atherogenic it might exert both anti- and pro-atherogenic effects, 
depending on the inflammatory context.127 Neutrophils are important for 
atherosclerosis through their interactions with damaged endothelium, recruitment of 
other leukocytes and development of foam cells.113,128,129 
The concept of the “psoriatic march” suggests a pathogenetic link between psoriasis 
and cardiometabolic comorbidities (Figure 3). According to this hypothesis, the 
systemic inflammation in psoriasis induces insulin resistance. Insulin resistance 
triggers widespread endothelial cell dysfunction, which leads to atherosclerosis and 
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myocardial infarction or stroke.130 The hypothesis of inflammation spreading from 
psoriatic plaques through the vessels is supported by the parallel alteration of 
cytokine patterns in the skin and blood compartment. Mediators originating from the 
skin may include cytokines from infiltrating immune cells and molecules secreted 
from resident cells in response to the cytokine milieu, such as abnormal amounts of 
pro-inflammatory adipokines (adiponectin, leptin, and resistin)131 produced by altered 
dermal fat underlying psoriatic lesions,132 and adipocytes. These adipokines may thus 
synergise with psoriatic cytokines and drive a local inflammatory condition, which 
over time leads to a widespread vascular and systemic inflammation (Figure 3). 
However, neither the precise role of local adipose tissue in psoriatic pathogenesis nor 




Figure 3. The concept of the ‘psoriatic march’. It suggests a causal link between psoriasis as a 
systemic inflammatory condition and cardiovascular comorbidity, as systemic inflammation may 
cause insulin resistance, which in turn triggers endothelial cell dysfunction, subsequently leading to 
atherosclerosis and finally myocardial infarction or stroke (red, bold). This ‘backbone’ may be 
developed further by adding additional ‘modules’, such as a possible feedback of insulin resistance to 
epidermal homeostasis (red, fine). Obesity is a known risk factor for psoriasis and may induce the 
phenotype through systemic inflammation (orange, bold). Continuous effective systemic therapy may 
stop the ‘psoriatic march’ through interference with insulin resistance and endothelial dysfunction 
(green). Figure and text adapted from Boehncke et al., 2011.130 Reprinted with permission from John 
Wiley and Sons. 
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Besides potential systemic effects, the impact of the local inflammatory milieu on the 
vessel walls in the immediate vicinity is of importance. It is well known that 
inflammatory mediators induce and modulate the expression of adhesion molecules 
and influence local recruitment of circulating inflammatory cells to the respective 
sites.134-136 At this level, the development of a psoriatic plaque and an atherosclerotic 
plaque show many similarities.137 Of note, pro-inflammatory cytokines with known 
relevance in psoriasis are capable of inducing insulin resistance in endothelial 
cells,130,138,139 referring to the observation that a number of pro-atherogenic effects are 
still being triggered within these cells, while anti-atherogenic effects are blocked. 
Dermal endothelial cells are particularly sensitive to this phenomenon.139 The 
anatomical proximity between cytokine-producing psoriatic plaques and dermal 
blood vessels, exposes these cells to risk of turning insulin resistant, resulting in a 
state of dysfunction and stiffness. This results in an augmented peripheral resistance 
in the circulation, increased heart work, arterial hypertension, and finally 
macroscopic vascular disease in the form of atherosclerosis. Thus, high systemic 
levels of inflammatory mediators produced in psoriatic skin are not required for a 
plausible explanation of how psoriasis may drive cardiovascular disease.80,140 
1.3.2 Other comorbidities 
Psoriasis patients can have a severely reduced quality of life,141-144 and the risk of 
depression is increased, with possible biochemical links.145-147 Although many factors 
can contribute to depression in psoriasis patients, a growing body of evidence 
indicates that inflammation plays a role in pathophysiology of mental illnesses, 
including major depression.148 Numerous studies demonstrate elevated levels of CRP 
and pro-inflammatory cytokines in patients with depression, including TNF, IL-1β, 
and IL-6.146,148,149 These cytokines, which are involved in the psoriatic pathogenesis, 
cross the blood brain barrier and interact with pathophysiological spheres involved in 
depression.148 Psoriasis is an independent risk factor of non-alcoholic fatty liver 
disease (NAFLD) in patients who are 55 years or older.150 NAFLD is also associated 
with a chronic inflammatory state with increased levels of CRP, IL-6 and TNF, 
although a causal relationship has not been proven.150 Psoriasis is also associated with 
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Crohn´s disease with probable shared features with respect to cytokines, T cell 
involvement and amelioration of symptoms by neutralising TNF and IL-12/23.151-156  
1.4 Treatment 
1.4.1 Non-biological treatment 
Most people with psoriasis have localised disease where topical therapy forms the 
cornerstone of treatment. Glucocorticoids, vitamin D3 analogues, and keratolytic 
agents such as salicylic acid and urea, are used for local treatment. Several 
combinations and formulations (creams, ointments, solutions) are available.157,158 The 
topical retinoid tazaroten is also an effective treatment option for psoriasis patients.158 
However, in patients with extensive disease (>10% of body surface area affected) or 
affection of areas where topical treatment is ineffective, such as nail disease, a second 
line treatment is recommended, either phototherapy or systemic non-biological 
therapy.23 
Ultraviolet (UV) light is a commonly used treatment modality. 311 nm narrowband 
UVB light is particularly effective, with 70% of patients reaching PASI75.159-162 By 
using a combination of topical or systemic psoralen and UVA (PUVA), up to 90% 
achieve PASI75 response.163 Further, a combination of coal tar and UVB light, named 
The Goeckerman Regimen, is an effective and safe, although time-consuming 
option.164  
Methotrexate (MTX), a folic acid antagonist which inhibits DNA synthesis and cell 
replication but also has specific T cell-suppressive effects, is a widely used systemic 
drug for psoriasis treatment.158 Up to 50-60% of patients achieve PASI75, but severe 
side effects can limit the use. These include teratogenicity, bone marrow suppression, 
liver fibrosis and cirrhosis and rarely pulmonary fibrosis.1,158 
1.4.2 Biological treatment 
Biological drugs are protein-based drugs derived from living cells cultured in a 
laboratory,165 including fusion proteins, recombinant proteins, and monoclonal 
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antibodies. Biological drugs have revolutionised the treatment of patients with 
moderate-to-severe psoriasis and are given to those who do not respond to other 
treatments. Biologics are given by subcutaneous injections or intravenous infusions to 
patients with moderate-to-severe psoriasis that have not responded due to earlier 
treatment failure, intolerance or contraindication to conventional therapies or 
phototherapy. Biologics are more expensive than conventional systemic drugs, but 
the clinical efficacy is higher and risk of adverse events lower.166 In psoriasis, the 
biologicals used target the TNF/IL-23/IL-17 axis (Figure 4).  
 
Figure 4. Biologic treatments targeting the TNF/IL-23/IL-17 axis in psoriatic skin. An initial 
trigger (e.g. biochemical stimuli, infections) induces cell damage, NETs formation and increased 
production of antimicrobial peptides (e.g. LL-37). Self-nucleic acids and LL-37 complexes induce 
IFN type I production of activated pDCs stimulating maturation of cDCs followed by production of 
IL-12, IL-23, and TNF. The pro-inflammatory cytokine IL-23 drives T cell differentiation and 
stimulates production of Th22/ILC3 (IL-22) and Th17/ILC3 (IL-17) cytokines, while IL-12 initiate 
Th1 differentiation and subsequent TNF secretion. The released cytokines stimulate the proliferation 
of keratinocytes with neutrophilic inflammatory infiltrate. The schematic depicts biologics targeting 
TNF, IL-12/23, IL-23, and IL-17 cytokines highlighting the central role of this signalling pathway in 
psoriasis. cDC conventional dendritic cell, IFN interferon, IL interleukin, ILC innate lymphoid cell, 
LL37 cathelicidin, NETs neutrophil extracellular traps, pDC plasmacytoid dendritic cells, Th T 
helper lymphocyte, TNF tumour necrosis factor. Figure and text adapted from ten Bergen et al., 
2020.72 Reprinted with permission from John Wiley and Sons. 
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In the early 2000s the pathogenesis of psoriasis was proposed to rely on Th1 
responses, due to the increased lesional expression of Th1 cytokines, such as IFN-γ, 
TNF and IL-12.61 Moreover, the astonishing therapeutical efficacy observed when 
blocking TNF167,168 and the p40 subunit of IL-12 strengthened this hypothesis.61,169 
However, concomitant to the development of a monoclonal antibody targeting p40, 
IL-23 was found to contain the identical p40 subunit.170 Later, IL-23 was established 
to induce IL-17-producing CD4+ T cells, later named Th17 cells.171,172 The enhanced 
efficacy of novel biologics targeting IL-17 and the specific p19 subunit of IL-23 
along with the effects of IL-17 in murine models of psoriasiform inflammation, 
stresses the importance of IL-17 in psoriasis.61 Moreover, the primary mechanism of 
action by TNF inhibitors in psoriasis is thought to be an indirect inhibition IL-17 
signalling via the regulation of IL-23 production from DCs.173 Altogether, these 
findings indicate that psoriasis is a disease driven by IL-17 rather than Th1 cytokines, 
and that successful biological treatment mainly depends on its ability to block IL-17 
signalling.61,173 
TNF inhibitors 
The first generation of anti-psoriatic biologics targets the cytokine TNF. By inhibiting 
TNF they break the self-sustaining cycle of DC- and T cell-activation, and cytokine, 
growth factor and chemokine production by multiple cell types including 
lymphocytes, neutrophils, DCs and keratinocytes.174 Neutralisation of TNF with 
etanercept leads to a reduced cytokine production by inflammatory DCs and Th17, 
indicating that TNF directly regulates DC and Th17 cell function.14,175,176 TNF 
inhibitors are also effective as treatment of psoriatic arthritis.177 Currently, four TNF-
inhibitors are approved for the treatment of moderate-to-severe psoriasis, namely 
etanercept, infliximab (IFX), adalimumab and certolizumab pegol. Etanercept is a 
recombinant human TNF-receptor and Fc-fragment fusion protein, that neutralises the 
effects of endogenous TNF by competitively inhibiting its interaction with cell-
surface receptors.178 It is self-administered subcutaneously and about 50% of patients 
achieve PASI75.178-182 IFX is a chimeric monoclonal antibody, administered as 
intravenous infusion, which binds and neutralises TNF. It is the most effective TNF 
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inhibitor183 with PASI75 ranging from 75% to 88% in different randomised 
controlled trials.184-186 Adalimumab is a fully human monoclonal antibody, which is 
self-administered subcutaneously. 54-80% of patients reach PASI75.187,188 
Certolizumab consist of Fab fragments from humanised monoclonal antibodies 
conjugated to polyethylene glycol. As it does not have an Fc fragment, it does not 
cross the placenta.189 Patients using IFX have an increased risk of serious 
infections.190-193 All patients evaluated for therapy with a TNF inhibitor needs to be 
tested for latent tuberculosis, as there is an increased risk of re-activation.194 Another 
side effect observed in 2–5% of patients treated with a TNF inhibitor is “paradoxical 
psoriasis”,195 with inflammatory skin lesions caused by overactive innate 
inflammatory response, driven by pDC-derived type I IFNs that does not lead to T-
cell autoimmunity which is common in plaque psoriasis.196 Due to the involvement of 
TNF in body weight homeostasis, weight gain is frequently seen in IFX-treated 
patients.197 
IL-12/23 inhibitor 
Ustekinumab is a human monoclonal antibody which binds to the p40 subunit on IL-
12 and IL-23. About 70% of patients reach PASI75. When comparing ustekinumab to 
IFX, PASI75 does not differ significantly, but in contrast to IFX, ustekinumab does 
not induce weight gain.198 Drug survival of ustekinumab is better than that of TNF 
inhibitors both for biologic-naive and biologic-experienced patients with psoriasis.199 
IL-23-p19 inhibitors 
The humanised monoclonal antibodies tildrakizumab and risankizumab and the fully 
human monoclonal antibody guselkumab bind to the p19 subunit of IL-23. In head-
to-head trials the IL-23-p19 inhibitors are superior to ustekinumab with regards to 
clinical efficacy,200,201 suggesting that neutralisation of p19 more potently inhibits IL-
23,202 and indicating that IL-12 has a less important role in maintaining the psoriatic 
plaque. During clinical trials, no significant safety issues were observed. In 
guselkumab-treated patients, the most common adverse events were non-serious 
upper respiratory tract infections, nasopharyngitis, headache and arthralgias.203 There 
are no reports of increased rates of malignancy, serious and opportunistic infections 
 30
or major cardiovascular events.204 However, as these agents are novel there is a lack 
of long-term follow-up studies and experience regarding their use. 
IL-17 inhibitors 
Three monoclonal antibodies against IL-17 have been approved for the treatment of 
psoriasis, namely secukinumab, ixekizumab and brodalumab. Ixekizumab and 
secukinumab target IL-17A directly. Brodalumab blocks the receptor subunit IL-
17RA. Secukinumab,205-207 brodalumab208 and ixekizumab209 have all demonstrated 
superiority to ustekinumab for achieving PASI75 and PASI90. Thus, neutralising IL-
17 is more effective than neutralising IL-12/IL-23. Moreover, beneficial efficacy of 
both secukinumab210 and ixekizumab211 compared to etanercept, has been observed. 
In brodalumab-treated patients with underlying psychiatric disorders there have been 
a few cases of suicides, raising concerns regarding its safety, although causality never 
has been established.212 Inhibition of IL-17 slightly increases the risk of opportunistic 
infections, especially mucocutaneous candida and slightly increases the risk of 
triggering or worsening inflammatory bowel disease.213 Loss of IL-17 may facilitate 
inflammation in the gastrointestinal tract by favoring Th1 pathways or by changing 
the human mycobiome balance in the gut.214 A likely cause is that IL-17 has an 
important function in gut homeostasis and resistance to extracellular 
microorganisms.215-218  
Biosimilars 
Biosimilars are biotechnologically manufactured products entering the market when 
the original biological loses its patent. Biosimilars have the same amino acid 
sequence as the originator drug but are not exact copies of the originator product. Due 
to the complex structure and manufacturing process, the biosimilars are prone to 
variation, and regulatory rules are more extensive than those of generic versions of 
chemically synthesised drugs.219,220 However, no long-term efficacy and safety 
studies, which are required for originator biologicals, are performed for biosimilars 
prior to their approval, raising concerns regarding their efficacy and safety.221   
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1.4.3 Personalised treatment 
For every single patient that undergoes a consultation with a physician, resulting in 
some sort of treatment, the received treatment is personalised. However, in the 
context of biological treatment, a lack of robust methods to guide choice of treatment 
is evident, and the clinical treatment strategies are largely empiric.  
Some patients are primary non-responders to biologics. A significant proportion of 
psoriasis patients experience loss of effect of biological treatment, more frequently if 
concomitant MTX has not been used.222-224 The efficacy of biologics can be limited 
by immune reactions in patients. This can result in anti-drug antibodies (ADA) that 
neutralise the drug and reduce its efficacy, by altering pharmacodynamics and 
pharmacokinetics, with subsequent loss of response and increased risk of allergic or 
infusion reactions, serum sickness, bronchospasm, and vasculitis, some with fatal 
outcome. ADAs and a decline in serum trough levels are sometimes detected.225-227 
The different biological drugs have various risk of inducing neutralising ADAs. 
Neutralising ADAs have been identified in patients treated with IFX, adalimumab 
and ustekinumab.228 Etanercept, however, is not associated with neutralising ADAs. 
Anti-etanercept antibodies have been identified, but they have all been non-
neutralising.224 Neutralising ADAs to secukinumab have not been identified either, 
though caution, due to shorter experience with secukinumab, must be taken.229 
Structural components of biological drugs have been proposed as causes of 
immunogenicity. The murine components of IFX at the drug target’s binding sites, 
likely induces an antigenic reaction specific to them.230 Contrarily, the binding sites 
of etanercept are naturally occurring type II (p75) receptors. This suggests 
immunogenicity against other portions that do not compromise the therapeutic 
activity of etanercept.230 In vitro, neutralising anti-adalimumab antibodies specifically 
confined to the TNF-binding region of adalimumab has been identified.231 Further, it 
has been speculated that ADAs can form immune-complexes with adalimumab, 
leading to accelerating adalimumab clearance, due to shorter half-lives of immune 
complexes compared to free-standing antibodies.224,232 Although the mechanisms 
behind ADAs are not fully understood, their effects are clinically significant.224 
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Measurements of trough level and ADAs have been outlined for clinical use (Figure 
5).227 However, they leave room for misinterpretation due to different and non-
standardised methodologies and recommendations, which can be confusing. Some 
prediction of treatment responses within an ongoing treatment course is possible by 
utilising drug trough level and ADA measurements,227,233 but they cannot be used as 
predictive tools before treatment with a biological drug.  
 
 
Figure 5. Proposed treatment decision tree when monitoring drug levels in patients on biologics 
starting with TNF inhibitors. Figure and text adapted from Carrascosa et al., 2014.227 Reprinted with 
permission from John Wiley and Sons. 
  
Still, when a patient experiences worsening of the disease, it is difficult to know if the 
problem is a flare of the disease, loss of efficacy or poor treatment adherence. Thus, 
there is a clinical need for better tailored therapy, based on predictive assays for 
monitoring and understanding disease and drug reactions in patients. 
A method used to measure levels of functionally available drug, reporter-gene assay, 
utilises a genetically TNF-sensitive reporter gene cell line to quantify residual drug 
activity and levels of neutralising ADAs in sera from anti-TNF-treated patients.234 
This leads to the question if a patient’s own cells can be used as reporters of TNF 
activity, and moreover, reporters of IL-12, IL-23 and IL-17 activity. Can the activity 
of a psoriasis patient’s circulating cells serve as a measurement of disease activity 
and treatment efficacy? 
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1.5 Signalling pathways 
When thriving to gain knowledge about the immunopathogenesis of a disease, 
knowing which types of cells that are present and if any of these cells are abundant or 
deficient is of course important, but rarely sufficient. Often it is important to find out 
what the cells do. Cytokine levels supply information about the signalling 
environment between cells in the tissue. However, to find out which state each 
individual cell or cell population is in, measurement of molecules expressed by the 
cells only when in a certain state is necessary. The following paragraphs are limited 
to the molecules associated with immune cell activation that were used in 
experiments included in this thesis. 
1.5.1 Intracellular signalling pathways 
In response to a stimulus on the cell surface, the cell utilises many mechanisms to 
respond appropriately. To allow changes to occur in the timeframe necessary for 
cellular responses, the intracellular signalling systems use many enzymes as catalysts, 
including protein kinases that catalyse phosphorylation and adenylyl cyclase which 
catalyses formation of cyclic adenosine monophosphate. With respect to the 
cytokines TNF, IL-12, IL-23, and IL-17 which are targets for biological treatment of 
psoriasis, several signalling cascades are relevant. TNF signals via TNF-receptor 1 
and 2, which are expressed on all nucleated cells,235 and induces phosphorylation of 
NF-B, a transcription factor, and p38 mitogen-activated protein kinase (MAPK). 
TNF signalling can result in phosphorylation of signal transducer and activator of 
transcription 3 (STAT3), another transcription factor, and extracellular signal-
regulated kinases (ERK).236-239 IL-17 signals via somewhat similar pathways, with 
engagement of the IL-17 receptor leading to activation of TNF receptor-associated 
factor 6 (TRAF6), and subsequent phosphorylation of NF-κB as well as p38 and 
ERK.240 Binding of IL-12 and IL-23 induces receptor dimerisation of IL-12Rβ1/IL-
12Rβ2 and IL-12Rβ1/IL-23R, respectively, leading to activation of the kinases Janus 
kinase (JAK)2 and tyrosine kinase (TYK)2. Downstream, IL-12 leads to 





Figure 6: The intracellular signalling pathways involved in the pathogenesis of psoriasis. 
Cytokines involved in the pathogenesis of psoriasis induce different intracellular signalling 
transduction pathways, leading to gene transcription and subsequent production of cytokines, such as 
TNF, IFN-γ, IL-17 and IL-22. The MAPK signalling cascade can be induced by TNF, IL-17 and IL-
1, which results in activation of kinases and downstream activation of the MAPKs p38 and ERK that 
translocate to the nucleus. The NF-κB signalling cascade can be activated by TNF, IL-17, IL-23 and 
IL1, and leads to nuclear translocation of NF-κB. IL-12, IL-23, IL-6 and IFNs all stimulate the 
JAK/STAT signalling cascade, leading to activation of JAKs, which in turn activates STATs that 
translocate to the nucleus. ERK; extracellular signal-regulated kinase, IFN; interferon, IKK; inhibitor 
of κB kinase IL; interleukin, JAK; Janus kinase, MAPK; mitogen-activated protein kinase, NF-κB; 
nuclear factor kappa-light-chain-enhancer of activated B cells, STAT; signal transducer and activator 
of transcription, TNF; tumour necrosis factor.  Created with BioRender.com 
JAK/STAT  
The JAK/STAT signalling pathway regulates the cellular responses many cytokines 
and growth factors. By utilising intracellular tyrosine kinases called JAKs and 
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transcription factors called STATs, the pathway transduces a signal from the 
extracellular receptor to the nucleus. Binding of a ligand to the extracellular domain 
of a JAK-associated membrane-bound receptor results in JAK phosphorylation, 
which subsequently leads to phosphorylation, dissociation, dimerisation, nuclear 
translocation and DNA-binding STATs.244 The 4 different JAKs and 7 different 
STATs are functionally heterogenous and are activated by different ligands. 
Furthermore, serine kinases can phosphorylate the serine residue of STAT1 and -3, 
independently of tyrosine phosphorylation mediated by JAKs. Altogether, the 
JAK/STAT pathway, depending on extracellular ligands, results in differing 
signalling specificity. 
Cytokines elevated in psoriatic patients are prototypical stimuli of several STATs. 
For example, IL-12 and IFN-γ are strong activators of STAT4 and STAT1, 
respectively, but both can also activate STAT3.245-247 IL-6 and IL-2 are strong 
activators of STAT3 and STAT5, respectively.248,249 However, multiple cytokines 
transduce signals through the different STATs and the downstream cellular effects 
differ depending on the ligand. For example, both IL6 and IL10 signals through 
STAT3 but elicits distinct cellular effects, evidenced by their respective pro- and anti-
inflammatory activities in myeloid cells.247,250 Some mechanisms by which the JAK-
STAT pathway can be modulated are through the production of suppressor of 
cytokine signalling (SOCS) proteins, microRNAs, internalisation of the cell-surface 
IFN receptors and ubiquitin carboxy-terminal hydrolase 18.251 
In psoriasis, STAT3 has emerged as a key player in the development and 
pathogenesis, due to hyperactivation in lesional skin and its prominent role in Th17 
cell differentiation.252-254 Following IL-6-stimulation of naïve CD4+ T cells, STAT3 
upregulates IL-23R which is essential for IL-23 responsiveness and full effector 
functions and maintenance of Th17 cells.255-257 Moreover, phosphorylation of STAT3 
is thought to mediate the impaired function of Tregs seen in psoriasis patients.81 With 
regards to IL-17A production, STAT3 and -5 are functionally competitive. Both bind 
to the IL17a promoter. However, while STAT3 induces IL17a transcription, STAT5 
is a negative regulator.258,259  
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Signalling through STAT1 is generally pro-inflammatory, anti-proliferative and pro-
apoptotic.260 STAT1 has also been postulated as a suppressive factor for IL17a 
expression and Th17 cell development, 259,261,262 supported by impaired IL-17-
mediated immunity and STAT1 gain-of-function mutation in patients with chronic 
mucocutaneous candidiasis.263 Moreover, STAT1 activation has been reported to 
repress IL-22 gene expression and psoriasis pathogenesis in a imiquimod-induced 
murine psoriasis model.264 Also, in lesional psoriatic skin, increased level of 
phosphorylated STAT1, both serine and tyrosine phosphorylation, has been 
detected.265 STAT1 may therefore play a part in regulating the psoriatic inflammation 
through suppressing IL-17. However, as STAT1 is a key factor in the signalling of 
IFN-γ, which is abundantly expressed in psoriatic lesions, the role of STAT1 in 
psoriatic inflammation needs to be investigated further. 
Both STAT4 and STAT5 augment survival, proliferation and differentiation.260 
Signalling through STAT4 is activated by a variety of cytokines, including IL-12, 
IL-23 and type I IFNs. In response to IL-12, STAT4 promotes IFN-γ production and 
Th1 differentiation.266-268 In psoriatic skin, T cells have been described to have higher 
levels of phosphorylated STAT4 than those of non-psoriatic skin, increasing their 
response to IFN-α and subsequent upregulated IFN-γ production.266,269 STAT5 
signalling plays an essential role in the differentiation of Tregs by inducing the 
expression of the transcription factor, FoxP3,259,270,271 and is, thus, a potential 
negative regulator of psoriatic inflammation. 
In psoriasis patients treated with the IL-12/23 inhibitor ustekinumab, the 
transcriptional activity of STAT1, -3, and -4 was silenced in peripheral blood.272 Thus, 
the JAK/STAT pathway plays an important role in the psoriasis pathogenesis, and 
further knowledge is needed to fully elucidate its role in the delicate interplay. 
 
MAPK 
Being among the most prevalent cascades in eukaryotes, the MAPK cascade regulates 
several fundamental cellular processes including proliferation, differentiation, and 
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apoptosis.273-275 Members of the MAPK family are typically activated by serial 
phosphorylation and activation of upstream kinases. MAPKKK phosphorylates 
MAPKK which in turn phosphorylates MAPK.274,275 MAPK, the effector of the 
pathway, acts on hundreds of substrates including transcription factors and -
suppressors, and chromatin remodelling proteins. MAPKs comprise four subfamilies, 
namely ERKs, JUN N-terminal kinases (JNK), p38 and ERK5.274,276 
The ERK1/2 pathway can enhance the production of pro-inflammatory cytokines, 
such as TNF,277 IL-6278 and anti-inflammatory cytokines including IL-10.279 
Moreover, inhibition of ERK phosphorylation by chloroquine reduces TNF gene 
expression in several cell types.277 ERK signalling is typically triggered by growth 
factors, such as epidermal growth factor. Interestingly, the epidermal growth factor 
receptor is up-regulated in active psoriatic lesions, and inhibition of this receptor in 
cancer patients with psoriasis has improved their psoriatic lesions.280 
Activation of p38 is associated with production of cytokines including IL-6, IL-1β 
and TNF281. Phosphorylated p38 has been detected in lesional psoriatic epidermis.282 
Activation of p38 is mainly induced by environmental stress and inflammatory 
stimuli and cytokines, such as IL-1 and TNF.274 Fumaric acid esters, used in the 
treatment of psoriasis, effectively inhibit the activity of p38 MAPK, decreasing pro-
inflammatory cytokine production.283  
 
NF-κB 
The NF-κB protein complex regulates genes that control transcription of cytokines 
important in psoriasis pathogenesis and genes regulating cellular differentiation, 
survival, and proliferation.284-286 
The NF-κB network consists of five family member protein monomers, p65 (RelA), 
RelB, cRel, p50 and p52. These monomers form homodimers or heterodimers that 
bind DNA differentially287-289 and are regulated by two pathways – the canonical 
(classical) or non-canonical (alternative) pathway.290 
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In the canonical, NF-κB essential modulator (NEMO)‐dependent pathway, receptor 
activation leads to activation of kinase complexes consisting of the adaptor protein 
NEMO and two inhibitors of κB (IκB) kinases (IKKα and IKKβ). This IKK-complex, 
once activated, phosphorylates IκB, leading to ubiquitination and proteasomal 
degradation. Following degradation of IκB, associated NF-κB dimers, predominantly 
RelA/p50, are released and translocated to the nucleus. After IκB release, the NF-κB 
subunits are subjects to a variety of posttranslational modifications, e.g. 
phosphorylation286,291, that fine-tune gene expression control.290,292 The canonical 
pathway responds to diverse stimuli, including ligands of various cytokine receptors, 
TNF receptor (TNFR), TLR and B and T cell receptors. In contrast, the non-
canonical, NEMO-independent pathway, responds to a more specific group of 
stimuli, which includes ligands of a subset of the TNFR superfamily. It relies on the 
activation of IKKα which phosphorylates p100, resulting in its ubiquitination and 
proteasomal processing to p52. This process results in the nuclear translocation of 
RelB/p52 dimer and the following upregulated gene transcription.293 Functionally, the 
canonical pathway is involved in almost all aspects of the immune responses, whilst 
the non-canonical pathway regulates specific processes, such as immune cell 
maturation and differentiation and lymphoid organogenesis. However, the evident 
crosstalk between these two pathways290 has led to the suggestion of viewing them as 
a single NF-κB signalling system.294-296 
NF-κB is one of the most important regulators of pro-inflammatory gene expression. 
Synthesis of cytokines important in psoriasis, such as TNF297,298, IL1β299, IL6300 and 
IL8301, is mediated by NF-κB.285 Suppression of apoptosis has been proposed as a 
mechanism responsible for epidermal thickness in psoriasis. Altered NF-κB 
signalling changes the balance of signals from B-cell lymphoma (Bcl)-proteins and 
cyclins. Survivin, an anti-apoptotic factor, increased in psoriasis also relies on NF-
κB.284,302-306 Furthermore, psoriatic skin displays increased level of phosphorylated 
NF-κB/RelA307 and positive epidermal staining of NF-κB.285 Also, NF-κB-induced 
microRNA-31 promotes epidermal hyperplasia.308 Altogether, the literature implies 
that NF-κB is a key player in the pathogenesis of psoriasis. 
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1.6 Literature search 
The literature search was completed 29th of November 2020. 
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2. Aims 
In this thesis we wanted to combine immunological assay development as well as 
clinical and biological investigations with the overall aim of gaining insights to 
psoriasis treatment and deepening understanding of disease pathophysiology.  
The specific aims were to: 
 
• Develop robust functional cell-based assays to monitor drug-targeted 
intracellular signalling pathways in psoriatic peripheral blood immune cells. 
• Investigate frequencies of peripheral blood cell subpopulations and their 
respective activity of drug-targeted intracellular signalling pathways in 
psoriasis patients with active or biopharmaceutical-treated disease, and healthy 
controls. 
• Compare clinical parameters, and intracellular signalling activity in peripheral 
blood cells, in psoriasis patients treated with originator infliximab and the 
biosimilar CT-P13. 
• Search for psoriasis-specific peripheral blood immune signatures and 
biomarkers of treatment response. 
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3. Materials and methods 
3.1 Materials 
3.1.1 Study population 
The biobank used for these studies was started and organised by Dr Silje M. Solberg. 
101 patients diagnosed with psoriasis and found eligible for biological treatment at 
the Department of Dermatology, Haukeland University Hospital, Bergen, Norway, 
were included from April 2015 to September 2018. To be included in the study, 
patients needed to be at least 18 years old, have moderate-severe psoriasis and being 
prescribed biological drugs. About half the cohort were included prior to initiation of 
biological treatment. The rest were already treated with a biological drug at inclusion. 
Blood samples from healthy controls were obtained, spread throughout the year, from 
the blood bank at Haukeland University Hospital, Bergen, Norway. All healthy 
controls were non-psoriatic. Further, they were age-, sex- and BMI-matched. The 
studies presented here, and the biobank were approved by the regional ethics 
committee (2014/1489 and 2014/1373). All patients and controls signed a written 
informed consent. External funding sources did not influence planned methods, data 
analyses of presentation of results.  
3.1.2 Sample collection, handling and storage 
Blood was collected at the laboratory of the Department of Dermatology, Haukeland 
University Hospital, to be further processed and stored at Broegelmann Research 
Laboratory. Blood samples from each patient were collected in lithium-heparin tubes 
at inclusion, and after approximately 3 and 12 months. Peripheral blood mononuclear 
cells (PBMCs) were isolated by immediate density gradient centrifugation with 
Lymphoprep (Axis-Shield Ltd, Dundee, Scotland). The cells were added to a mixture 
containing 42,5% freezing medium (ProfreezeTM CDM), 50% serum-free media (X-
VIVO-20TM, Lonza, Basel, Switzerland), and 7,5% dimethyl sulfoxide (DMSO). At a 
concentration of 5x106/ml, the PBMCs were stored in aliquots of 1 ml in a freezing 
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chamber (CoolCell®) at -70°C allowing reproducible freezing rate of 1°C/min. The 
following day the PBMCs were moved for long-time storage in liquid nitrogen.  
3.1.3 Collection and storage of patient data  
Patients filled out DLQI themselves, whilst the clinical evaluation, including PASI, 
was performed by a medical doctor. Patients were, most often, evaluated by the same 
clinician at every visit, to avoid inter-individual variation. Gender, age, and BMI 
were registered as well as clinical and biochemical data. Collected data was stored, 
unidentifiable, on the research server from Helse Vest with the opportunity of patient 
identification by a digital key, as required by the regional ethics committee. 
3.2 Methods 
3.2.1 Phospho-specific flow cytometry 
Flow cytometry is a laser-based technology, which allows rapid, high-content 
multiparameter analysis of single cells. Cells in fluid suspension are 
hydrodynamically focused to separate from each other.309 The fluid stream passes 
through one or more lasers, with the resulting fluorescent and scattered light detected 
by a photomultiplier tube (PMT), where it is amplified, and converted to a voltage 
pulse which is converted to a digital value.310 Each measurement is performed on a 
single particle, allowing identification, and grouping of individual particles, for 
example as cellular subpopulations. Fluorescent agents, most often fluorochrome-
conjugated monoclonal antibodies, are used to further identify the characteristics of 
individual particles. The fluorochrome is excited by a specific wavelength of light 
provided by a laser and emits light with a lower specific wavelength. The emitted 
light of specific wavelength is discriminated by use of optical filters before detection 
of the emitted light, which greatly increases the number of parameters which can be 
detected. Flow cytometry is well suited for measuring frequencies of cellular 




Figure 7: A typical flow cytometry experiment. Sample preparation from blood often involves 
Ficoll gradient separation of mononuclear cells, and sometimes cryopreservation, before staining 
with fluorescent antibody conjugates. Each of these steps can introduce variability in the assay 
results. Instrument setup involves setting voltage gains for the photomultiplier tubes (PMTs) to 
achieve optimal sensitivity. To the extent that this is not standardised, it becomes a source of 
variability as well. Data acquisition involves passing the stained cells through a laser beam and 
recording the fluorescence emission from all the bound antibody conjugates. Here, the main variable 
is the type of instrument, including the lasers and optical filters used. This is followed by data 




By use of phospho-specific flow cytometry, it is possible to measure the 
phosphorylation status of proteins critical to intracellular signalling cascades at the 
single-cell level (Figure 8). It combines identification of cellular subtypes through 
CD-markers, with the analysis of intracellular signal transduction pathways, thereby 
identifying the activation of different cell functions, such as transcription of pro-
inflammatory cytokines. 312,313 
By phospho-specific flow cytometry we measured frequency and intracellular 
phosphorylation of PBMC subpopulations from psoriasis patients and healthy 
controls. Cryopreserved PBMCs from patients and healthy controls were thawed, and 
incubated for 2 h at 37 °C, 5% CO2. Cells were divided and either stimulated for 15 
min with TNF or left unstimulated. Following fixation and permeabilisation with 
paraformaldehyde and methanol, the cells were stained according to a 4 x 2 barcoding 
grid using 4 and 2 different concentrations of the succinimidyl ester dyes pacific blue 
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and pacific orange, respectively. 8 barcoded samples were combined into one tube, 
allowing simultaneous antibody staining and data acquisition, with the different 
samples being distinguishable during software analysis based on their fluorescence 
intensities of the barcoding dyes. After staining cells with antibodies reactive to cell 
surface- and intracellular antigens, acquisition on a LSRI Fortessa flow cytometer 
with BDFACSDiVaTM Software (both BD Biosciences) was performed. An internal 




Figure 8. Basic steps in phospho-specific flow cytometry. 1: A heterogeneous sample of cells is 
treated with different stimuli, to induce distinct signalling cascades and phosphorylation of target 
proteins. 2: The cells are then fixed, permeabilised, and stained with fluorophore-conjugated 
phospho-specific antibodies and surface markers to identify cell types. 3: The cells are then analysed 




3.2.2 Mass cytometry 
Mass cytometry couples flow cytometry with mass spectrometry314,315 and has 
expanded the number of detectable targets to > 40 on a single cell level (Figure 
9).316,317  
 
Figure 9. Workflow of a Typical Mass Cytometry Experiment. 
Single cells are acquired, and a viability stain is applied to mark dead cells for exclusion from 
analyses. Fixation can optionally be applied at this point to preserve the cell state. Multiple samples 
can be barcoded with unique combinations of heavy metal tags, enabling them to be pooled together 
prior to staining to minimise technical variability at this step. After pooling samples into one tube, 
cells are then incubated with antibodies targeted against proteins of interest. Cell permeabilisation 
can be performed if intracellular targets are to be measured. Cells are nebulised into droplets as they 
are introduced into the mass cytometer. They then travel into an inductively coupled argon plasma 
(ICP), in which covalent bonds are broken and ions are liberated. The ion cloud is filtered by a 
quadrupole to remove common biological elements and enrich the heavy metal reporter ions to be 
quantified by time-of-flight mass spectrometry. Ion signals are integrated on a per-cell basis, 
resulting in single-cell measurements for downstream analysis. Data are compiled in an FCS file that 
can then be parsed and plotted in a variety of ways. Figure and text adapted from Spitzer et al., 
2016.317 Reprinted with permission from Elsevier 
 
Mass cytometry uses heavy metal isotopes not commonly found in nature, instead of 
fluorophores, for labelling probes, thereby typically avoiding overlap between 
detection channels.317 Cells in suspension are nebulised, and travel through 
inductively coupled argon plasma, where covalent bonds are broken, resulting in free 
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ions.318,319 The ion cloud is filtered by a quadrupole for removal of common 
biological elements, which enriches the quantification of heavy metal reporter ions by 
time-of flight mass spectrometry. The velocity of lighter ions is higher and reach the 
detector before the heavier ions which have lower velocity.314,318 The ion counts are 
converted into electrical signals and into a data matrix where every column represents 
a distinct isotope and each row represents a single mass scan of the detector. Isotopes 
with different atomic masses can be identified with minimal signal spillover between 
channels.320 
The actual work in the lab is very similar for mass cytometry as for phospho-specific 
flow cytometry. However, it differs slightly. Firstly, cisplatin was used as an 
identifier of dead cells, 321 and was added before cells were stimulated and fixed. 
Secondly, staining of surface antigens, was done before permeabilising the cells, and 
in study III the chemokine receptors were stained before fixation. Thus, 2-3 steps of 
staining were needed. Thirdly, iridium, which intercalate DNA, was used as a cell 
identifier.  
3.2.3 Data processing and statistical analysis 
Initial visualisation and processing of data was done in FlowJo version 10.2. For flow 
cytometry experiments compensation was done in FlowJo, by use of compensation 
beads. Deconvolution of barcoded samples was done by gating on relevant 
combination of barcoding dyes. Gating on monocytes (MC) and lymphocytes and 
removal of doublets was based on light scatter properties. Further identification of 
PBMC subpopulations was based on relative expression of light from fluorochrome-
conjugated antibodies bound to CD-molecules. Further analysis of flow cytometry 
data was performed in cytobank by analysing median fluorescence intensities (MFI).  
Mass cytometry data was normalised to beads. Deconvolution of barcodes was done 
using Fluidigm software and the debarcoding module in the Astrolabe Cytometry 
Platform322 in study III. In study III, removal of beads, doublets, dead cells, and 
debris was done in FlowJo by manual gating, before uploading the clean fcs-files to 
Cytobank Cellmass v7 for further data analysis.   
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Historically, single-cell data is examined in two dimensions at a time in scatter plots, 
but with increasing number of parameters the number of scatter plots becomes 
overwhelming, and the risk of overseeing multivariate relationships increases. Due to 
the complexity of mass cytometry data, computational tools for dimensionality 
reductions and cell clustering have been developed.324 To project high-dimensional 
data to lower dimensionality, which is more easily interpreted, dimensionality 
reduction algorithms are needed. The t-distributed stochastic neighbour embedding (t-
SNE) algorithm measures pairwise distances between all cells in the high-
dimensional space to determine each cell's location on a two-dimensional plot. The 
result is a mapping of high-dimensional data onto two dimensions yet conserving the 
dimensional structure of the data.325,326 Clustering algorithms segregate similar cells 
into groups that can be evaluated as one entity. FlowSOM uses self-organising maps 
(SOM), which is an unsupervised technique for clustering and dimensionality 
reduction, and can reveal how all the markers behave on the individual cells and 
identify subsets easily missed by manual gating.327 In FlowSOM, all cells from all 
samples are brought together in a matrix. The matrix is used to train a SOM, which 
results in a grid of nodes corresponding to clusters of cells. Approximate nodes 
represent more similar populations than distant nodes. The clustering is visualised by 
a minimum spanning tree. The assigning of a metacluster to each cluster, effectively 
groups them into populations.327 In study III, FlowSOM was used to identify the 
PBMC subpopulations (Table 1).  
For study II, single-cell data was clustered using the FlowSOM R package327 and 
labeled using the Ek'Balam algorithm.322 Cell subset definitions followed Maecker et 
al.,310 and Finak et al. (Table 2),328 with the addition of mDCs. Cluster labeling, 
method implementation, and visualisation were done through the Astrolabe 
Cytometry Platform (Astrolabe Diagnostics, Inc.). Differential abundance analysis 
was done using the edgeR R package329,330 following the method outlined by Lun et 
al..331 Differential expression analysis was done using the limma R package332 
following the method outlined by Weber et al..333 Inverse hyperbolic sine (asinh) 
calculations all used a cofactor of 5. 
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Data from study 1 and 3 were transferred to the statistical package for social science 
(SPSS) Statistics 24 for statistical analysis. Since flow and mass cytometry generally 
is not normally distributed, non-parametric tests were used for comparison; Mann-
Whitney U test for independent, unpaired data, and Wilcoxon signed-rank test for 
paired data (between inclusion and follow-up). For correlation analyses in study 3, 
the strength of correlations revealed by Spearman's rank order test were interpreted 
according to the recommendation from British Medical Journal 
(https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-
one/11-correlation-and-regression), with rho 0.00-0.19 regarded as very weak, 0.20-
0.39 as weak, 0.40-0.59 as moderate, 0.60-0.79 as strong and 0.80-1.00 as very strong 
correlation.  
Fold changes (FC) of MFI and median signal intensities (MSI) for samples relative to 
corresponding internal control was used in study I and III, to overcome inter-assay 
variation. FC of follow-up samples relative to corresponding inclusion value 
(Timepoint 2/Timepoint 1 or Timepoint 3/Timepoint 1) were also used in study I and 
III, to analyse individual variation over time. 
Figures in study I and III were made in GraphPad Prism v8.0 and Cytobank Cellmass 
v7. Figures in study II were generated in Astrolabe Cytometry Platform (Astrolabe 
Diagnostics, Inc.). 
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B cells CD3-CD14- CD19+CD56- 
  B naive CD27- 
  B memory CD20+CD27+ 
  Plasmablast CD20-CD27+CD38+ 
T cells CD3+CD14-CD19-CD56- 
 Double negative CD4-CD8- 
 CD4+ CD4+CD8a- 
  Naive CD27+CD45RA+ 
  Central memory (CM) CD27+CD45RA- 
  Effector memory (EM) CD27-CD45RA- 
  Terminally differentiated (EMRA) CD27-CD45RA+ 
 CD8+  CD4-CD8a+ 
  Naive CD27+CD45RA+ 
  Central memory (CM) CD27+CD45RA- 
  Effector memory (EM) CD27-CD45RA- 
  Terminally differentiated (EMRA) CD27-CD45RA+ 
NK cells CD3-CD14-CD19-CD56+ 
  Natural killer (CD56+CD16+) (NK) CD16+ 
  Natural killer (CD56+CD16-) (NK) CD16-CD56++ 
NKT-like cells CD3+CD14-CD19-CD56+ 
Dendritic cells CD3-CD14-CD19-CD56- 
  Conventional dendritic cells (cDC) CD11c+CD16-CD123- HLA-DR+ 
  Plasmacytoid dendritic cells (pDC) CD11c-CD123+HLA-DR+ 
Monocytes CD3-CD19- 
  Classical monocytes CD14+CD16- 
  Intermediate monocytes CD14+CD16+ 




4.1 Study I 
Phosphorylation of intracellular signalling molecules in peripheral blood cells 
from patients with psoriasis on originator or biosimilar infliximab 
In this study, we included 19 healthy controls and 25 patients with psoriasis vulgaris 
who had all been diagnosed with severe psoriasis at an earlier timepoint but were now 
in or close to remission (PASI 0–4) with frequent infusions of originator IFX. In total, 
22 patients were randomised, either to continue originator IFX or to switch to the 
biosimilar CT-P13 as part of another study,154 and therefore these samples were 
analysed double blinded. The final three patients continued treatment with originator 
IFX. PBMCs from healthy controls and patients at three timepoints (0, 3 and 12 
months), were analysed by use of phospho-specific flow cytometry. The MFI of 
fluorochromes conjugated to antibodies against phosphorylated NF-κB, ERK1/2, p38 
and STAT3 was used as a measurement of phosphorylation level and signalling 
activity. 
The basal phosphorylation of NF-κB, ERK1/2, p38 and STAT3 was significantly 
higher in patients at inclusion compared to healthy controls in almost all cell 
populations analysed, despite having achieved clinical remission by treatment with 
IFX. At 12 months, patients still displayed significantly higher basal phosphorylation 
levels than healthy controls, but the number of epitopes with significant differences 
was decreased.  
The FC (TNF-stimulated MFI divided by corresponding unstimulated cells) which is 
the phosphorylation level after stimulation with TNF relative to the basal 
phosphorylation level, was significantly lower for pSTAT3 in MCs, T-, B- and NK 
cells, pERK in T cells and pNF-κB in NK cells at inclusion compared to healthy 
controls. After 12 months, only FC of pNF-κB in MCs and NK cells in addition to 
pSTAT3 in MCs were decreased in patients compared to healthy controls. 
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No differences in basal phosphorylation of NF-κB, ERK1/2, p38 or STAT3 were 
detected between patients treated with originator IFX and the biosimilar CT-P13. FC 
of pSTAT3 in B cells was increased in patients on CT-P13 compared to patients on 
IFX after 3 months, but this difference was not present after 12 months. 
 
4.2 Study II 
Mass cytometric analyses of peripheral blood mononuclear cells from psoriasis 
patients on anti-TNF treatment 
PBMCs from 10 patients and 6 controls, included in Study I, were used for mass 
cytometric analyses of cell frequencies and differential expression of molecules 
associated with cell activation. In the patient cohort, 5 of the patients continued 
originator IFX, the other 5 switched to CT-P13 after the first blood sample was 
obtained.  
No obvious differences in cell frequencies were observed between patients and 
controls, nor between the two treatment cohorts.  
Differential expression analyses of asinh-transformed MSI displayed a significantly 
higher expression of CD38 on NK cells from patients compared to healthy controls. 
This was seen in both CD16+ and CD16- NK cells, but the difference between 
patients and healthy controls was statistically significant only in the parent 
population. A trend with higher expression of CD38 on T cells from patients was also 
observed, particularly on CD4+ effector memory T (TEM) cells , but also on CD4+ 
central memory T (TCM) and terminally differentiated effector memory T (TEMRA) 
cells this was seen. A higher expression of CD38 on mDCs was also seen in patients 
compared to healthy controls. The expression HLA-DR was slightly increased in 
CD16+ NK cells and decreased in mDCs and pDCs from patients compared to healthy 
controls. 
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Patients at inclusion displayed a higher basal level of pSTAT3 in CD16- NK cells, 
CD4+ TEM and CD4+ TEMRA than healthy controls. Basal phosphorylation level of NF-
kB was higher in MCs and DCs from patients than those from healthy controls, 
particularly in CD14-CD16+ MCs and mDCs. In patients, higher levels of pERK in 
NK cells, both CD16- and CD16+, than in healthy controls, were observed. CD4+ TEM, 
CD14-CD16+ MCs and pDCs from patients had higher basal levels of pp38 than those 
from healthy controls. However, none of these results were statistically significant 
after adjusting for multiple comparisons. 
No obvious differences were observed between the patients continuing IFX compared 
those switching to CT-P13 with regards to basal levels of CD38, HLA-DR, pERK, 
pNF-κB, pp38 and pSTAT3. However, the CT-P13-treated patients had a decreasing 
trend of most activation markers, which was not obvious in the IFX-treated patients.  
Upon stimulation with TNF patients displayed lower FC (TNF-stimulated asinh-
transformed MSI value minus basal asinh-transformed MSI value) of pNF-κB and 
pp38. The most obvious differences were for pNF-κB in CD16+ NK cells, CD8+ 
TEMRA cells and CD14+CD16- MCs, and pp38 in CD8+ TEMRA and CD16+ NK cells. 
 
4.3 Study III 
Mass cytometry analysis of blood immune cells from psoriasis patients on 
biological therapy 
PBMCs from 32 patients with severe psoriasis were analysed using mass cytometry 
before and 4 and 12 months after initiation of biological therapy using IFX, 
etanercept, ustekinumab or secukinumab. 
After receiving biological therapy, a shift in the Th1/Th2 balance was detected in 
psoriasis patients. At inclusion patients had a higher number of Th1 cells and lower 
number of Th2 cells compared to healthy controls and follow-up. Patients had higher 
fractions of Th22 and Th9 cells at inclusion compared to 1-year follow-up. Patients 
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tended to have reduced frequency of Tregs at inclusion and 4 months, but after 1 year 
the level had normalised. A shift from naïve/effector (CD45RA+) to memory 
(CD45RO+) predominance in the CD4+ population, including Tregs, was seen during 
biological treatment. Further, the frequency of and CD8+ memory T cells (CCR4+) 
was higher in patients at inclusion compared to healthy controls.  
Programmed cell death protein 1 (PD-1) expression was higher on Th2 cells and 
lower on CD8+ T cells from patients with active disease than those from healthy 
controls. After 1 year, the expression of PD-1 on CD4+ T cells, including Tregs, from 
patients had an increased.  
At inclusion, patients displayed increased levels of phosphorylated p38 in Th2 cells 
and Tregs, ERK in CD4+ T cells and STAT1 in classical MC compared to healthy 
controls. Increased phosphorylation was still evident at both follow-up time points in 
Th2 cells and after 1 year and for ERK in CD4+ T cells. The level of phosphorylated 
STAT1 and p38 decreased in classical MC during the first 4 months of treatment and 
the level of pSTAT1 in Th17 cells was reduced after 1 year. 
Responders had a negative correlation between PASI improvement and FC of Th17 
cell frequency after 4 months (Timepoint 2/Timepoint 1), and FC of CD8+ T cells 
after 1 year (Timepoint 3/Timepoint 1). Non-responders had a decrease of NK and 
NKT-like cells after 4 months relative to inclusion. Moreover, CD45RA/RO ratio in 
Tregs at inclusion was lower in responders compared to non-responders. Responders 
had higher FC of PD-1 on CD4+ T cells after 4 months and on NK cells after 1 year. 
The expression of the epithelial-homing receptor CCR10 on B cells was higher in 
patients than healthy controls at inclusion. Responders had higher FC of epithelial-
homing CCR10 on Th cells, CD8+ T cells and B cells after 4 months and on NK and 
Th17 cells at 1 year follow-up compared to non-responders. Non-responders had 
higher pSTAT1 in Th17 cells, pp38 in classical MC, and pNF-κB and pp38 in 
intermediate MC, at inclusion, than responders. Responders had higher FC of pp38, 
pSTAT1 and pNF-κB in non-classical MC and lower FC of pSTAT3 in intermediate 
MC compared to non-responders after 1 year. 
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5. Discussion 
5.1 Methodological considerations 
5.1.1 Common considerations for single cell analyses 
Patients and controls: Study I included 25 patients and 19 healthy controls, study II 
included 10 patients and 6 healthy controls and study III included 32 patients and 10 
healthy controls. In all three studies, cryopreserved PBMCs from a single donor buffy 
coat were included in each experimental run as an internal control to check and adjust 
for inter-assay variation. In all three studies, a large number of variables from 
relatively small patient cohorts were analysed with the risk of false positive results 
due to multiple comparisons.334,335  no corrections for multiple comparisons were 
made in study I and III. No power calculations were done for any of the three studies. 
Nevertheless, these studies aimed to assess biologically relevant differences in 
PBMCs and should therefore be considered despite low power. PBMC isolation: To 
minimise basal phosphorylation, a colleague previously tested how different 
anticoagulants in test tubes affected basal phosphorylation. Lithium-heparin tubes 
followed by density gradient separation of PBMCs showed significantly lower basal 
phosphorylation of ERK, p38, STAT1, STAT3 and STAT5 in multiple cell types than 
those isolated through CPT sodium citrate and sodium heparin tubes.336 
The effect of freezing and thawing cells: To enable simultaneous analysis of many 
samples, PBMCs were cryopreserved. To optimise viability and recovery of 
cryopreserved cells, serum support media, such as foetal bovine serum (FBS), are 
commonly used as freezing media. To avoid unspecific stimulation caused by FBS, 
our freezing mixture contained a non-animal origin chemically defined freezing 
medium, ProFreezeTM-CDM, a serum-free media, X-VIVO-20TM and cryoprotectant 
DMSO. To ensure a constant freezing rate of 1°C/minute, CoolCell® freezing 
chambers were used for freezing of samples.337 The combination of cooling cells at a 
controlled rate and the use of DMSO minimises damage to the cells by increasing 
permeability of the plasma membrane and preventing the formation of ice 
crystals.337,338 To avoid ice re-crystallisation and osmotic stress and to maximise cell 
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recovery and viability, the cell were thawed rapidly at 37°C.337 After thawing, a 
resting period of 2 hours was included, to allow cells to recover.336,339,340 
Antibody selection and titration: When designing the panel, the surface antigens were 
selected based their ability to differentiate PBMC subpopulations. The choice of 
phospho-epitopes were in study I and II based on relevant signalling pathways 
through TNF-stimulation. In study III, more phospho-epitopes were included to 
account for T cell differentiation and the general cytokine milieu. All antibodies were 
titrated for their specific experimental conditions to find their optimal staining 
concentrations. For all surface molecules, the lowest concentrations that resulted in 
clear separations between negative and positive populations were chosen. For 
phospho-specific antibodies the optimal dilutions were defined as the lowest 
concentrations resulting in clear separations between unstimulated and stimulated 
populations. Correct titrations of antibodies and suitable choices of metal isotopes or 
fluorochromes for antibody conjugations are crucial for acquiring precise single cell 
data by flow and mass cytometry, particularly when measuring changes in 
intracellular signalling transduction. Unwanted interactions may occur, despite 
extensive efforts to reduce experimental artefacts. In addition, purity of 
isotopes/fluorochromes, density of the measured molecule, and the sensitivity of 
different channels can influence the signal detection. A general rule is, therefore, to 
assign low-frequency molecules to sensitive channels and vice versa, and to avoid 
spillover from abundant molecules or bright channels to neighbouring channels.341  
Stimulation: The stimulation of cells is also a crucial step. Both concentration and 
timing need to be perfected. The cells were rested for 120 minutes at 37°C, 5% CO2, 
to reduce the basal signalling levels following the process of thawing. TNF was 
diluted in X-VIVO-20TM. The cells were stimulated for 15 minutes with TNF at a 
concentration of 50 ng/ml. Cells that were not stimulated were added the same 
volume of X-VIVO-20TM to ensure equal cell concentration but also to expose them 
to the same drop in temperature as the stimulated cells, by leaving the incubator 
during the stimulation step.  
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Fixation and permeabilisation: The recognition of signalling activation is through 
detection of phosphorylation of proteins. Detection of phosphorylated proteins brings 
challenges different to detection of surface proteins alone. These proteins are 
localised intracellularly and are therefore inaccessible to the fluorochrome- and 
metal-conjugated antibodies. Moreover, after stimulation, phosphorylation is a 
transitional event, i.e. the phosphorylated protein is not stable.312 To overcome these 
problems, the cells are fixed and permeabilised to stabilise the phosphorylated 
proteins for detection and to allow entry of phospho-specific antibodies.312 Choosing 
fixation and permeabilisation agents are based on optimising the detection of 
phosphorylation while preserving the stability of molecules. Consequently, all 
antibodies used for antigen detection were validated on cells following fixation and 
permeabilisation.  
Barcoding: Barcodes label individual samples with a unique signature of dyes/metals 
and enables multiplexing of the samples prior to staining and acquisition on a flow or 
mass cytometer. Fluorescent cell barcoding was used in study I and mass-tag cell 
barcoding was used in study II and III. Following barcoding, the samples can be 
pooled together into one tube, allowing simultaneous staining and data 
acquisition.342,343 This reduces antibody consumption, increases throughput, shortens 
acquisition time and reduces staining variability. For fluorescent cell barcoding, used 
in flow cytometry, pacific orange and pacific blue were utilised. Pacific orange and 
pacific blue are fluorescent dyes that react to amine groups on protein lysine residues 
and at the N-terminus.342 Barcodes used for mass cytometry were palladium (Pd)-
based. Using different combinations of the six isotopes of Pd, were each sample is 
either positive or negative for each of the six epitopes, twenty different combinations 
are possible. Thus, a unique combination is generated for each sample which is used 
to identify the sample when deconvoluting the barcodes (Figure 10).343 
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Figure 10. Palladium (Pd) barcoding. Each kit has 20 unique barcodes generated from 6 Pd 
isotopes, where combinations of 3 isotopes are used to identify each sample. This is called a "6-




5.1.2 Flow versus mass cytometry 
Developments in the field of conventional flow cytometry are constantly increasing 
the dimensionality of acquired data, both through novel hardware and novel probes 
with reduced promiscuity.344 However, conventional flow cytometry panels 
exceeding 18 channels are reserved for the few, due to spectral overlap.345 Further, a 
flow cytometry panel with many channels will need compensation to deal with the 
spectral overlap which can interfere with the accuracy of the results. With mass 
cytometry, this is barely an issue, and panels exceeding 40 markers is possible.317,320 
However, with mass cytometry many of the events will be lost before it reaches the 
detector, making it a less sensitive method than flow cytometry. Moreover, as the 
biological material is lost during a mass cytometric analysis, sorting of cells after 
analysis is not possible. Also, mass cytometry is more expensive. Another difference 
between flow and mass cytometry is the range of signal intensities, where the metal 
isotopes used in mass cytometry all have similar signal intensities, and the 
fluorophores used in flow cytometry have a larger range of signal intensities. A large 
range of signal intensities can complicate panel design but can also be an advantage if 
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detection of a lowly expressed molecule, is needed, e.g. a phospho-epitope. 
Altogether, mass cytometry is a better tool for explorative studies, whilst flow 
cytometry should perhaps be the preferred method if you know what you are looking 
for. Finally, flow cytometric assays are already established in clinical practice. Thus, 
flow cytometric research results are yet more easily translated to clinical practice. 
5.1.3 Phospho-specific flow cytometry: Special considerations 
The laborious process of designing a panel for phospho-specific flow cytometry had 
already been accomplished by a colleague in our group to study PBMCs from 
patients with Sjögren's syndrome.336 With small modifications, his method was 
implemented to our patient samples. Precautions had to be taken regarding signal 
spillover when designing the antibody panel. The choice of fluorophores was 
therefore a compromise between the wavelengths of the available lasers, the filters on 
the flow cytometer, availability of the chosen fluorochrome-conjugated antibody. The 
phospho-epitopes where expected to display very subtle differences, making it very 
vulnerable to compensation. Therefore, minimising spillover into important and 
sensitive channels, such as the phospho-antigens, was key to reduce compensation. 
However, due to availability some concession had to be made. For example, the anti-
STAT3 (Y705) was conjugated to PerCP-Cy5.5, which is a relatively dim 
fluorophore, and thus, not best for use on a sparsely expressed molecule.  
Single fluorescent-stained compensation beads were used for the measurement and 
compensation of fluorescent spillover. Further, as fluorescent cell barcoding included 
two very bright fluorophores (pacific blue and pacific orange), a residual vial holding 
barcoded cells, without fluorescent antibodies, was analysed to control fluorescent 
spillover from the barcoding. Moreover, BD cytometer setup and tracking beads were 
used for determining minimum baseline PMT voltages and monitoring cytometer 
setup and performance (laser alignment, laser time delay, and sensitivity).346  
5.1.4 Mass cytometry: Special considerations 
Panel design: The MaxPar panel designer and panel wheel were used to check for 
signal spillover and tolerance for each channel. Although no major spillover was 
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detected, spillover from channel +/-1 and +16 which corresponds to oxidated metals 
should be considered. The purity of isotopes, to which degree a molecule is present 
and different sensitivity of channels can influence signal detection.341 Barium 
contamination has for long been an issue, as it may interfere with analytical readout. 
Barium occurs naturally as a mix of several stable isotopes, though mainly 138 Ba 
and 137 Ba.347 Many sources of barium contamination have been identified, including 
purified bovine serum albumin (BSA), commercial salts used to prepare phosphate-
buffered saline (PBS) and dish soaps used to clean buffer containers. Moreover, other 
researchers using the Core Facility for Flow Cytometry have seen that latex powder 
free gloves also are a significant source of barium. To overcome this issue great 
precautions were taken on choice of material and washing procedures prior to sample 
acquisition. 
To identify dead cells when analysing the data, cisplatin had to be added prior to 
fixation and permeabilisation. Thus, in study II, cisplatin was added to the cells 
before stimulation with TNF. This could affect basal phosphorylation levels and how 
the cells responded to TNF-stimulation. This was, however, a necessary compromise.  
In study II and III, slightly different definitions for non-classical MCs were applied. 
In study II non-classical MCs were defined as CD14-, whilst in study III they were 
defined as CD14low. However, they stand for the same population, despite differing 
terminology. 
In study III, the antibodies for CXCR3, CCR4, CCR6 and CD127 were added to live 
cells before fixation, barcoding and permeabilisation, because they were sensitive to 
fixation.348 Moreover, for study III some markers in the panel were prone to some 
signal overlap. A lot of effort was put in to optimise this panel, but due to availability 
of antibodies, some compromises had to be made. CCR4 (175Lu) and pSTAT3 
(158Gd) had medium tolerance, were in the medium sensitivity area of the machine 
and had medium overlap. CD45RA (143Nd), CCR10 (164Dy), PD-1 (155Gd), pERK 
(167Er) and pNF-κB (166Er) all have low tolerance for spillover. However, except 
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for CD45RA, these markers were assigned to relatively sensitive channel. Further, we 
did not experience any obvious problems with CD45RA. 
As mass cytometry overcomes the limitations of spectral overlap associated with flow 
cytometry, compensation controls are not required. Polystyrene bead standards, called 
EQTM four element calibration beads (containing 140/142Ce, 151/153Eu, 165Ho and 
175/176Lu) were used to monitor changes in instrument performance and signal 
fluctuations during acquisition of data and across assays, to minimise inter- and intra-
sample variations. 
5.1.5 Data analysis 
Multivariate data can be difficult to visualise and interpret, merely due to the number 
of data points and dimensions. With an increasing number of variables, it is 
increasingly clear that you are overpowered by the sheer load of information. In the 
flow cytometric analysis, the number of variables were limited, and the PBMCs were 
therefore, by manual gating, divided into lymphocytes and MCs based on their size 
and granularity in forward vs. sideway scatter plots, before being divided into B cells, 
T cells, NK cells and NKT-like cells based on their expression of CD19, CD3, CD56 
and CD56/CD3, respectively. For the mass cytometry data in study II and III, 
however, manual gating on biaxial plots was not feasible and would involve high risk 
of error. Analysis of high-dimensional cytometric data bring computational 
challenges in terms of data pre-processing, normalisation, dimensionality reduction 
and clustering.349 Many of the algorithms used for high-dimensional data circumvent 
the traditional approaches for flow cytometric data, fundamentally altering the 
processing and interpretation. The large number of available algorithms, such as 
viSNE, SPADE, X-shift, PhenoGraph, FlowSOM and Citrus, and the missing 
consensus on best practices for data pre-processing and analysis are issues that need 
to be addressed.350,351 Pipelines using different tools are frequently developed, making 
it increasingly challenging to comprehend the considerations for each approach and 
understand what kind of biological insight you can obtain from it. In study III 
FlowSOM was the chosen algorithm for defining the PBMC subpopulations used for 
downstream functional analysis, largely due to the availability in cytobank and the 
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ability to combine dimensionality reduction and clustering in an unsupervised 
manner, but still being able to decide the number of clusters. In study II, a cloud-
based data analysis pipeline322 was used, which both clustered and defined the PBMC 
subpopulations but also directly did the group comparisons we sought. 
5.2 Biological and clinical implications of the results 
There is convincing support in the literature for systemic inflammation and increased 
risk of comorbidities like CVD in psoriasis patients.113,352 Biological therapy has been 
proven as very effective treatment of immune-mediated diseases like psoriasis, and 
the clinical efficacy of the four biological drugs used in our study, as measured by 
PASI and DLQI, was excellent. The following section will address biological 
interpretations of the single cell analyses and clinical implications of the findings. 
5.2.1 Abberant frequencies of immune cell subsets in psoriasis 
patients improves with biological treatment 
In study III, initiation of biological therapy led to a decreased fraction of Th1 cells, 
along with a significant increase in the Th2 fraction, i.e. a shift in the Th1-Th2 cell 
balance, which is in concordance with the findings of others.353 Increased fractions of 
Th1 cells has previously been detected in the blood of psoriasis patients with active 
disease354 and are thought to be recruited to the skin.124 Moreover, in psoriasis 
patients CD4+ T cells producing IFN-γ, the key cytokine of Th1 cells, have been 
shown to be increased.355 Contrarily, others have found circulating Th1 cells to be 
reduced and negatively correlated with PASI in psoriasis patients.356,357 Indeed, the 
hypothesised recruitment of Th1 cells from the circulation to the psoriatic lesion,124 
could result in a time-dependently reduced fraction of Th1 cells in the circulation, 
undetectable in our cohort. Also, in these studies, slightly different cell definitions 
were applied, and the cohorts differed both in size and disease activity.  
Th9 and Th22 displayed higher frequencies at inclusion compared to 1-year follow-
up, but not compared to healthy controls. Both Th22 and Th9 have been associated 
with active psoriasis, and are thought to actively participate in cutaneous 
inflammation.62 Aberrant frequencies of circulating Th22 cells but not Th9 cells have 
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previously been described in psoriasis patients.355 Moreover, Th22 cells has, along 
with Tc17 cells, been proposed as part of the site-specific disease memory in 
recurrent psoriasis,88,91 and could therefore be an interesting target to prevent chronic 
disease.  
Surprisingly, no changes were seen in the Th17 cell frequency, which previously has 
been described to be increased in patients compared to healthy controls.100 This study, 
however, defined Th17 cells based on the expression of IL-17A, while we defined the 
Th17 cells based on the expression of the chemokine receptor CCR6. Moreover, only 
patients with milder disease, based on PASI, not treated systemically were included. 
In our cohort, all patients had severe disease and 12 out of 34 patients were treated 
with MTX. Altogether, this can very well explain differing results.  
Patients with active psoriasis had reduced frequencies of Tregs. This was, however, 
normalised with biological treatment. This pattern has also been detected by others.353 
Tregs are important suppressors of inflammation.358,359 In psoriatic skin, Tregs are 
outnumbered by effector T cells and display a deficient suppressor activity. This 
combination leads to insufficient peripheral tolerance and hyperproliferation of 
autoreactive T cells.84 Interestingly, Tregs have been described as dysfunctional and 
low-frequent in peripheral blood from patients with acute coronary syndrome.360 
The elevated levels of skin-homing B cells in untreated patients compared to healthy 
controls is highly relevant in light of the recent discovery of antibodies against the 
autoantigen LL37.44,361 These cells could, possibly, be involved in an autoimmune 
response against skin autoantigens, and thus, represent a new treatment target. 
Although others have found CD8+ T cells in abundance in psoriasis patients 
compared to healthy controls, our comparison of psoriasis patients and healthy 
controls did not reach statistical significance.362,363 However, we did find that 
reduction of circulating CD8+ T cells correlated with PASI-reduction. Of note, the 
Tc17 phenotype (CD8+CCR6+CD161+) is thought to be involved in the autoantigen 
detection and IL-17 production in the early stage of the disease, and thus, is 
forwarded as a potential treatment target.364-366 In our study, a circulating Tc17 
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population was detected, but no statistically significant differences were observed 
between groups. CD8+CCR4+ memory T cells were significantly increased in 
untreated patients compared to healthy controls. Others have found that CD8+ TEM 
predominantly express CCR4.362 Interestingly, it has been postulated that a fraction of 
resident CD8+ memory cells is released from chronically inflamed tissue to the 
circulation, contributing to the systemic inflammation associated with psoriasis.367 
After treatment initiation, CD4+ T cells including Tregs displayed an expression of 
CD45RO and CD45RA which increased and decreased, respectively. This 
demonstrates a shift towards an increased fraction of memory cells compared to 
naïve/effector cells, and is also in accordance with the findings of others.356  
5.2.2 Originator infliximab versus biosimilar CT-P13 
Clinically, switching from originator IFX to CT-P13 has been reported as non-
inferior to continued treatment with originator IFX for treating inflammatory bowel 
disease, spondylarthritis, rheumatoid arthritis, psoriatic arthritis and chronic plaque 
psoriasis. However, the study was not powered to show non-inferiority in the 
individual diseases.154 Comparing the two patient groups receiving originator IFX or 
CT-P13 by flow and mass cytometry, there were no significant differences in basal 
phosphorylation after 3 and 12 months. In study I, FC of pSTAT3 (Y705) in B cells 
was significantly increased after 3 months in patients who switched to CT-P13 
compared to those continuing treatment with originator IFX. As basal 
phosphorylation was similar between the two groups, the difference is most likely 
due to an increased activation upon TNF stimulation. However, this difference was 
not evident after 12 months. Of note, patients in the CT-P13 group had a tendency of 
a reduction in the activation molecules when comparing the 12 months sample to 
inclusion, which was not present in the originator IFX group to the same degree. This 
might reflect differences in structure and efficacy of the two drugs. This was not a 
phenomenon exclusively present in NK cells, which could have been predicted due to 
difference in afucosylated glycans and affinity for FcgRIIIa and FcgRIIIb. 
Altogether, our results strengthen the hypothesis of CT-P13 being a non-inferior 
treatment alternative to originator IFX. 
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5.2.3 Increased expression of molecules associated with cell 
activation in immune cells from psoriasis patients 
T cell activation requires interactions between the T cell receptor on the T cell and 
HLA, which have strong genetic association to psoriasis, on the APC.14 
Simultaneously, co-stimulatory signals are required for T cell activation. Conversely, 
co-inhibitory signals can stop the activation. PD-1 is one of the molecules which 
silences the power of this mechanism. Furthermore, inhibition of PD-1 or its ligand, 
PD-L1, releases the “break” on the immune system, and leads to a stronger immune 
response. This principle is exploited in cancer immune therapy.368 In our study, 
patients with active psoriasis displayed a decreased expression of PD-1 on CD8+ T 
cells and an upregulation of PD-1 on CD4+ T cells including Tregs during the follow-
up period after treatment initiation. Moreover, responders had a significantly higher 
FC of PD-1 in CD4+ T cells and NK cells than non-responders, which means they had 
a higher increase of PD-1 in the follow-up period after treatment initiation. These 
findings implicate an impaired interaction between PD-1 on T cells and its ligand on 
the APC, which in turn leads to an up-regulated immune response, a pattern 
previously described in psoriasis patients.369 Blockade of PD-1 has been 
demonstrated to augment Th1 and Th17 responses and suppress the Th2 response.370 
To find out whether this pattern of differing PD-1 expression is a specific disease 
mechanism or a mere consequence of chronic inflammation, more research is needed. 
Patients with severe psoriasis had elevated levels of intracellular phosphorylation in 
Th2 cells and Tregs, in addition to classical MCs. Increased phosphorylation in CD4+ 
T cells from psoriasis patients has also been found by others,362 and earlier studies of 
inflammatory disorders have found that activation levels of PBMCs decrease with 
successful treatment.353,371  
In study I and II, our findings of elevation of phosphorylation levels in distinct 
immune cell subsets in IFX-treated patients support that there is an ongoing systemic 
inflammation which persists after resolution of skin manifestations, without 
correlation to trough level or length of IFX treatment prior to inclusion. Possibly, 
ceasing systemic inflammation is a slower process than ceasing skin inflammation. 
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Another possibility is that signalling of the measured pathways is maintained by other 
mediators than TNF,371,372 as neither of the pathways are TNF-specific. Also, 
mutations in genes encoding NF-κB and MAPK or inhibitors of NF-κB could explain 
increased activity of the signalling pathway, despite years of treatment.34 Hence, 
therapy targeting intracellular signalling cascades could be of interest. However, 
these signalling cascades are involved in general cell processes, and serious side 
effects of such therapies are, thus, likely. 
The reduction, but not complete normalisation of the intracellular signalling cascades 
underlines the chronicity of the disease. An important question is therefore if long-
term systemic treatment is advisable, not only to treat the skin lesions, but also to 
reduce the risk of comorbidities. 
In study II, higher expression of CD38 and HLA-DR in PBMC subsets from patients 
than healthy controls, were found. In general, CD38 and HLA-DR are more highly 
expressed on activated immune cells. HLA-DR is a major histocompatibility 
complex, constitutively expressed on DCs, MCs, macrophages and B cells, which 
typically appears at the late stages of NK and T cell activation373-375. Moreover, the 
less mature CD56bright population of NK cells with high functional activity also co-
expresses HLA-DR.376 CD38 is a multifunctional ecto-enzyme, predominantly 
expressed on immune cells. It metabolises nicotinamide nucleotides to adenosine 
diphosphate ribose (ADPR) and cyclic ADPR (cADPR), which are potent 
intracellular Ca2+-mobilising compounds.377 Indeed, CD38 is present on activated 
immune cells. This is possibly due to its function of promoting metabolic collapse in 
pathogens by degrading nicotinamimide adenine dinucleotide (NAD+) and its 
precursors.378 Further, CD38 binds to CD31, and thus, confers lymphocytes with the 
ability to adhere to endothelial cells, a necessary step in extravasation. The increased 
expression of CD38 particularly on NK and CD4+ TEM cells, most likely represents an 
activated state of these cells, despite being in clinical remission. 
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5.2.3 Stratification of responders and non-responders 
The findings in study I and II implicate an ongoing systemic inflammation despite 
amelioration of skin lesions. Due to low PASI, absence of ADAs, normal drug trough 
level, and normal blood values, a correlation between functional markers by flow and 
mass cytometry and routine clinical and biochemical markers was not possible to 
detect. In study III, some predictive potential for disease severity and treatment effect 
was detected. 
Levels of circulating NK and NKT cells have been reported to be lower in psoriasis 
patients than in healthy controls,379-381 although contradictory findings exist.382,383 
During follow-up of the patients in study III, responders had a higher increase in the 
frequency of NK and NKT-like cells. The increase in NKT-like cells during follow-
up also correlated with PASI improvement. Interestingly, responders had a 
significantly higher fraction of memory Tregs than non-responders during active 
disease. Thus, the fraction of memory Tregs serves as a possible biomarker for 
prospective stratification of treatment response. 
At inclusion, non-responders had higher pSTAT1 in Th17 cells, pp38 in classical 
MC, and pp38 and pNF-κB in intermediate MC than responders. This indicates that 
early stratification based on cell-based immune profiling may be used to predict 
treatment response, and perhaps also to steer the choice of biological agent. However, 
our data cannot be used to identify cut-off values of different markers, which is 
necessary for translation to clinical practice. For this, larger studies are needed. 
Surprisingly, responders had a higher expression of the epithelial-homing marker 
CCR10 on circulating CD4+ T cells including Th2 and Th17 cells and on CD8+ T 
cells, B cells and NK cells, compared to non-responders. This could, however, 
represent sustained production of skin-homing PBMCs despite reduced expression of 
ligands in the skin, or it could represent efflux from healed skin.356,367 
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5.2.4 Relation to comorbidities 
Being a systemic immune-mediated disease with associated comorbidities, there has 
been an increasing interest regarding the risk-lowering impact of biological treatment 
on comorbidities in psoriasis patients.130,367 
Inflammation is important in CVD, highlighted by the protective effects of aspirin, 
colchicine and canakinumab in CVD patients.113,384-386 Large observational studies 
have reported reduced incidences of cardiovascular diseases in patients treated with 
MTX387 and TNF inhibitors.388,389 Although others have failed to document such 
protective effects, the control groups in these studies have either received 
phototherapy390 or other systemic agents.391 Further, in a study comparing the rate of 
cardiovascular events in patients treated with TNF inhibitors (etanercept, IFX or 
adalimumab) and MTX, only 1,5% of patients in the TNF inhibitor cohort 
experienced a cardiovascular event within 12 months compared to 4,1% in the MTX 
group,392 suggesting that the risk of cardiovascular events reduces over time with 
continued TNF neutralisation. 
Complementary to these results, several small, controlled trials have evaluated 
changes in level of biomarkers for CVD during systemic psoriasis treatment. Indeed, 
several groups reported amelioration of such markers, including cytokines, 
adipokines and endothelial dysfunction.113,393-396 Moreover, studies using FDG PET 
and FDG PET/CT have found decreased inflammation in the ascending aorta and 
carotid arteries in psoriasis patients treated with biologicals,397 but also here 
contradicting reports exist, and the only randomised, double-blinded study found no 
difference between patients treated with a TNF inhibitor and placebo.398,399 Also, 
carotid intima/media thickness has been reported to decline with systemic treatment 
of moderate-to-severe psoriasis.400 
Although the literature is still heterogenous, in part due to methodological 
differences, treatment with TNF inhibitors most likely exert some CV-protective 
effect. 
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In study III, patients with active disease had elevated frequencies of intermediate 
MCs compared to healthy controls, which decreased after treatment onset. Moreover, 
non-responders had higher levels of pNF-κB and pp38 in intermediate MCs than 
responders. An elevated level of intermediate MCs is associated with CVD,401,402 and 
could, thus, provide a immunological mechanism of CVD-risk in psoriasis patients. 
Also, the increased activation level of signal transduction pathways in non-responders 
compared to responders may also indicate a larger risk of CVD for non-responders.403 
The frequency of classical MCs, which also are associated with atherosclerosis, was 
lower in patients with active disease at inclusion than in healthy controls, but 
normalised after treatment onset. A possible explanation is that the MCs are recruited 
to the sites of inflammation, including the skin and the vessel wall, in patients with 
active psoriasis.404 Contrarily, non-classical MCs, which had higher basal 
phosphorylation levels in responders than non-responders after 1 year of treatment, 
are thought to have athero-protective effects.404 Altogether, the distribution of MC 
subpopulations indicates that biological treatment protects psoriasis patients against 
CVD.  
In study I and II, no differences in cell frequencies were seen between patients and 
healthy controls, which was expected as they were clinically in remission. However, 
increased levels of molecules associated with cell activation were observed, including 
CD38, HLA-DR and pNF-κB, pSTAT3, pERK and pp38. This indicates an ongoing 
systemic inflammation. Indeed, evidence points towards a decreased risk of CVD in 
biologically treated patients with severe psoriasis, as compared to patients receiving 
topical treatment only. However, the literature does not supply evidence showing that 
biological treatment of severe psoriasis reduces CVD-risk to that of the general 
healthy population. Indeed, our findings of ongoing systemic inflammation despite 
normalisation of skin lesions, together with contradictory reports regarding vessel 
inflammation,397-399 may represent that patients treated with biologics still have an 
increased risk of comorbidities, including CVD, compared to healthy controls, 
although reduced compared to active disease.  
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CD38 has been proposed as a possible aggravator of atherosclerosis, by mediating 
production of pro-inflammatory cytokines and inflammatory cell infiltration 
throughout the development of CVD, though further research is needed to confirm 
this hypothesis.405 NF-κB can also play a role in CVD. Its function in myeloid cells of 
promoting pro-inflammatory gene expression and conversion of macrophages into 
foam cells supports that it does. Moreover, in low-density lipoprotein (LDL) 
receptor-deficient mice, transgenic expression of a nondegradable IκBα in 
macrophages reduces lipid loading and foam cell formation, whereas myeloid cell-
specific IκBα deletion sensitises atherosclerosis development.294 Thus, the activity in 
the NF-κB pathway in myeloid cells can be an important factor for determining CVD 
risk. Activation of p38 is also known to play a crucial role in cardiovascular disease, 
and occurs in response to stress mediators, such as hypertension, oxidised LDL 
cholesterol, ischemia and vascular injury. Moreover, inhibition of p38 has been 
considered due to beneficial effects in cell culture and animal models in a number of 
CVDs.406,407 Increased levels of phosphorylated STAT1 can reflect an increased level 
of IFN-γ. Importantly, both phosphorylated p38 and NF-κB are downstream events of 
TNF binding. As previously mentioned, IFN-γ and TNF are thought to contribute to 
inflammatory atherogenesis in a synergistic manner.123 Thus, level of phosphorylated 
STAT1, p38 and NF-κB can possibly serve as biomarkers of cardiovascular risk in 
psoriasis patients. 
5.2.5 NK cells: A forgotten cell population in psoriasis? 
The role of NK cells in psoriasis is not fully elucidated and has been little in focus so 
far. NK cells are capable of producing cytokines central in the psoriatic 
pathogenesis.408 This combined with NK cells expression of two receptors that bind 
HLA class I (killer-cell immunoglobulin-like receptors and the C-type lectin-like 
molecule CD94⁄NKG2),409 which is closely associated with psoriasis 
susceptibility,8,27 highlights the likelihood of NK cell-involvement in the 
pathogenesis of psoriasis.382 Adoptive transfer of NK cells from patients with 
psoriasis into beige-SCID mice with transplanted autologous skin grafts has been 
reported to cause classic psoriasis histology,410 and activated NK cells in psoriatic 
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lesions have been reported to contribute to disease progression.411 Altogether, these 
findings suggest that NK cells may have been underappreciated contributors to the 
pathogenesis of psoriasis. 
As mentioned previously, a significant reduction in NK and NKT cell numbers in 
peripheral blood of psoriasis patients with a negative correlation of NK cell number 
and disease severity has been reported in previous studies.380 However, incongruous 
findings have been published.382,383 In our studies, NK cell frequencies were similar 
between patients and controls. However, most patients received systemic treatment, 
either MTX, a biologic, or both, which can affect the cell frequencies.412-414  
NK cells in peripheral blood has been demonstrated to have an increased expression 
of Fas and downregulated NKG2A in patients with new-onset psoriasis. This was 
speculated to be early markers NK activation and represent a pro-inflammatory 
phenotype of NK cells in psoriasis patients.382 In our studies, we found increased 
expression of pERK, pp38, which can mirror an increased cytotoxic activity.415,416 
Interestingly in this regard, a recent study reported an increased frequency of 
granulysin-expressing NK cells in peripheral blood of patients with severe psoriasis, 
which strengthens this hypothesis.417 Increased expression of pSTAT3 in CD16- NK 
cells can be a sign of an increased transcription of mediators important for 
inflammation, such as TNF and IFN-γ.418 CD56brightCD16- NK cells have previously 
been found to be actively recruited to psoriatic lesions and release high amounts of 
IFN-γ, contributing to disease progression.411 
In general, CD38 and HLA-DR are more highly expressed on activated immune cells. 
In study II, NK cells displayed increased levels of these markers, where CD38 was 
significantly increased in patients compared to healthy controls. In cytokine-activated 
NK cells CD38 expression is associated with an increased cytotoxic activity, most 
likely through mediating calcium-signalling which causes degranulation and release 
of granzymes and perforin.419,420 Further, increased expression of perforin in psoriatic 
epidermis421,422 and blood has been demonstrated.383 Also, a recent study 
demonstrated that CD38+ NK cells reduced the proportion of Tregs in patients with 
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rheumatoid arthritis.423 Thus, increased CD38 expression on NK cells could be an 
alternative explanation of the previously described reduced proportion of Tregs in 
psoriatic patients.424 CD38 expression has also been shown to be increased in NK 
cells during pregnancy, possibly explaining their enhanced response to influenza.419 
Importantly, psoriasis patients have a higher risk of serious infections and the risk 
increases with disease severity, either due to biologics or the disease itself, and are 
often recommended vaccination against influenza and S. Pneumoniae.425  
5.3 Limitations of the study 
In all three studies, due to expensive and work-laborious methods, sample size, i.e. 
number of patients and controls, was a compromise between chance of statistically 
significant results and expediency. Nevertheless, all studies, especially study II, 
would benefit from including additional patients and controls. Study II was the only 
study where results were adjusted for multiple comparisons, which is needed when 
analysing high-dimensional datasets. After these corrections, few significant 
differences were found, even though differences were seen with unadjusted p-values 
below 0,05. With such small sample size, it is probable that these corrections, 
although statistically correct, negatively affects the p-value, and thus, conceal 
biologically relevant results. 
Cryopreservation of blood samples can possibly affect cell recovery and intracellular 
signalling. However, it was required to combine the collection of blood samples 
during routine consultations with simultaneous analysis. Moreover, all samples from 
patients and controls underwent the same procedure, and the inter-individual variety 
of storage duration, did not reveal obvious effects on phosphorylation levels. Any 
error arising due to this would be a systematic one. 
As mentioned previously, for flow cytometry experiments it is advantageous to use 
dim fluorochrome-conjugated antibodies against abundant antigens and bright 
fluorochromes conjugated to antibodies against rare antigens. Therefore, the use of 
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anti-STAT3 (pY705) conjugated to PerCp-Cy5.5 was not optimal, but unfortunately a 
necessary compromise due to availability.  
When discussing the frequency of the cell subsets, it is important to be aware of that 
the measurement is merely the fraction of a larger parent population. Therefore, an 
increased frequency of a certain cell subset is not necessarily due to an increased 
number of the respective cell subset. It may as well be due to a decreased number of 
another cell subset. Thus, caution must be taken when interpreting frequencies of cell 
subsets, rather than true count comparisons. The importance of true or absolute 
counts is exemplified by the counting of CD4+ T cells in patients with HIV to stratify 
their risk of opportunistic infections.426,427  
As mentioned, in study III, antibodies for CXCR3, CCR4, CCR6 and CD127 were 
added before barcoding. This introduces the risk of inter-sample variation of staining. 
Moreover, in study III, Barcode Perm Buffer was likely to interfere with the detection 
of CCR10 and CD161, as their expressions were increased compared to test runs 
without barcoding. 
In study III, we defined Tregs as CD3+CD4+CD25+CD127-. To identify Tregs with 
confidence, FoxP3 should be included. Unfortunately, this was not possible due to its 
need for a specialised lab-protocol incongruous with the detection of phospho-
epitopes. 
In study I we did not include a live-dead marker. Pacific orange was of little value as 
the cells were permeabilised. A live-dead marker compatible with permeabilisation 
was tested, but due to fluorescent spillover it was excluded from the experiments. Our 
approach was therefore to gate very strictly on the lymphocyte and MC population. In 
a parallel assay we determined the viability in these gates by staining with 7-
aminoactinomycin D. The viability of the cells was above 98% in the lymphocyte 
gate and 95% in the MC gate. The addition of cisplatin in study II and III enabled 
exclusion of dead cells from the analysis. In all studies we can assume sufficient 
removal of dead cells. However, as these methods of dead cell exclusion do not 
differentiate between the different cell subsets, there is a risk of higher levels of 
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apoptosis in some subpopulations, particularly the rarer ones. Therefore, alterations 
of signalling caused by apoptotic cells cannot be ruled out, especially in the rare 
populations. 
A high inter-individual variation was observed for all studies with regards to 
phosphorylation levels and the differences observed between groups were subtle. 
Thus, caution must be taken when interpreting these results. More studies with 
increased number of patients and controls are needed to confirm our results. 
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6. Conclusions 
The three studies included in this thesis promote single-cell analyses as useful 
methods to approach an understanding of the complex immunological network in 
psoriasis. Also, these studies imply that patients with severe psoriasis have systemic 
inflammation, also when treated with biological drugs, with potentially increased risk 
of comorbidities. 
Study I: 
Psoriasis patients treated with IFX have higher phosphorylation levels in PBMCs 
than healthy controls, which does not completely normalise with ongoing treatment. 
This may reflect systemic inflammation despite treatment with a TNF inhibitor and 
amelioration of skin lesions. Switching to biosimilar CT-P13 did not affect clinical 
parameters or phosphorylation levels, supporting the hypothesis of CT-P13 being a 
non-inferior treatment alternative. 
Study II: 
Based on the expression of CD38 and HLA-DR, and the levels of phosphorylated 
NF-κB, p38, ERK and STAT3, NK cells, CD4+ TEM and TCM, mDCs, pDCs and non-
classical MCs from psoriasis patients are in a more active state than those from 
healthy controls, despite treatment with IFX or biosimilar CT-P13, with no obvious 
differences detected between the two treatment cohorts. This suggests an ongoing 
systemic inflammation, with sustained risk of comorbidities, such as CVD. 
Study III: 
Biological therapy facilitates a shift in the fraction of T cell subsets, an increased 
expression of PD-1 on T cells, and a less atherogenic MC-distribution. Intracellular 
phosphorylation level of PBMCs is higher in psoriasis patients than healthy controls 
and in non-responders than responders. Altogether these changes indicate reduction 
of systemic inflammation in response to treatment, and that broad immune profiling 
may enable stratification of patients with respect to ongoing and future treatment 
response.  
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7. Future perspectives 
Our findings of increased CD38, particularly in NK cells, but also in TEM, warrant 
further investigations, both due to a low number of patients and weak staining of 
CD56. Therefore, we are planning a flow cytometry assay looking at different surface 
activation markers for NK cells and T cells in a larger group of patients and controls. 
Importantly, as CD38 expression is easily quantified by flow cytometry, it could 
serve as a potential biomarker in the future. 
Further comparisons of responders and non-responders are needed. With basis in 
study III, a functional analysis of Tregs, comparing responders and non-responders 
would be interesting. Also, as the fraction of Tregs was higher in responders, than 
non-responders, further analyses of Treg fraction which includes analysis of FoxP3 
would be beneficial. Moreover, analysing absolute counts of Tregs could also 
generate important results. An absolute count is more likely to be robust in clinical 
practice because it is less prone to interference by the quantites of other cell subsets. 
Also, identifying patients who are non-responders to several biologics, with 
subsequent functional analysis of immune cells in peripheral blood and skin are in the 
planning. 
The aberrant frequencies in the MC compartment in untreated patients should be 
analysed further. Analyses of absolute counts would be preferred to analyses of cell 
fractions. Also, as NF-κB signalling in myeloid cells could be an important mediator 
of CVD risk,294 a focused assay looking at the NF-κB pathway in MCs and DCs 
could provide useful information regarding risk stratification. 
With regards to the signalling assays, we only measured a small fraction of each 
signalling cascade, where none of the phospho-epitopes are specific for an upstream 
event. In the future it would be advantageous to analyse larger fractions of the 
different cascades. When measuring pNF-κB, only the RelA-phosphorylation, the 
prototypical marker of the canonical NF-κB cascade, is analysed. However, by 
adding IκB and perhaps NEMO to the analysis, the activation level of these proteins 
these proteins would more certainly mirror the activity in the canonical NF-κB 
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signalling pathway. Moreover, when analysing the NF-κB signalling activity in 
dendritic cells, phosphorylated RelB should be included in the analysis. Although 
canonical NF-κB signalling often is thought to be synonymous with RelA activation, 
inflammatory dendritic cells also render RelB as a key transcriptional effector of the 
canonical pathway.290 
Peripheral blood cells and cytokines are promising biomarkers for estimating 
systemic inflammation in psoriasis and treatment response.371,428 In rheumatoid 
arthritis, a whole blood flow cytometric assay measuring baseline JAK 
phosphorylation has been speculated to enable prediction of treatment response of 
synthetic disease-modifying anti-rheumatic drugs.429 Moreover, a flow cytometric 
sputum assay measuring STAT1-phosphorylation has been reported to enable 
assessment of sensitivity to and efficacy of JAK-inhibition in chronic obstructive 
pulmonary disease.430 In this regard, testing a phospho-specific flow cytometry assay, 
measuring STAT phosphorylation in psoriasis patients before and during treatment 
with a JAK inhibitor could provide useful information. 
Finally, all our studies were based on peripheral blood, mainly due to the availability 
and the obvious advantages regarding biomarker discovery. Peripheral blood immune 
cells may be used as reporters of drug responses give insight to the pathophysiology 
of psoriasis. However, the primary site of inflammation is in the skin. Therefore, we 
plan to collect biopsies from psoriasis patients, for analyses by imaging mass 
cytometry. Imaging mass cytometry enables visualisation of many markers 
simultaneously, while preserving the tissue architecture.431 Thus, it can reveal the 
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Summary
Background Psoriasis vulgaris is a chronic, inflammatory skin disease characterized
by a dysregulated immune response and it is associated with substantial systemic
comorbidities. Biological drugs such as tumour necrosis factor (TNF)-a inhibitors
can ameliorate the disease but are expensive. Biosimilar drugs have the same
amino-acid sequence as the originator, but differences in manufacturing can
affect biological activity, efficacy and tolerability.
Objectives To explore potential differences in intracellular phosphorylation of sig-
nalling molecules in peripheral blood cells from patients with psoriasis treated
with the TNF-a inhibitor infliximab compared with healthy controls, and to
investigate if the phosphorylation pattern was influenced by switching from the
originator infliximab to the biosimilar CT-P13.
Methods By flow cytometry, we measured phosphorylation of nuclear factor kappa
B, extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase
and signal transducer and activator of transcription 3, before and after TNF-a
stimulation in monocytes and T, B, natural killer and CD3+ CD56+ cells from 25
patients with psoriasis treated with infliximab and 19 healthy controls.
Results At inclusion, phosphorylation levels of peripheral blood mononuclear cells
(PBMCs) were increased in patients with psoriasis compared with healthy con-
trols, even though clinical remission had already been achieved. Phosphorylation
levels declined in patients on both originator infliximab and biosimilar during
continued treatment. No significant differences were detected between the two
medications after 12 months.
Conclusions Patients with psoriasis on infliximab have higher activation levels of
PBMCs than do healthy controls, possibly reflecting systemic inflammation.
Switching from the originator infliximab to biosimilar CT-P13 did not affect
phosphorylation levels or clinical parameters, suggesting that CT-P13 is a non-
inferior treatment alternative to the originator infliximab.
What’s already known about this topic?
• The pathogenesis of psoriasis encompasses interactions between dendritic cells,
T cells, keratinocytes and neutrophils. Certain cytokines, including tumour necrosis
factor (TNF)-a, from these cells activate intracellular signalling cascades, which can
be measured using phospho flow cytometry.
• Infliximab and the biosimilar CT-P13, both effective in psoriasis, act by binding TNF-a.
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What does this study add?
• Peripheral blood mononuclear cells (PBMCs) from patients with psoriasis are more
activated with higher intracellular signalling activity than PBMCs from healthy
controls.
• This elevated activation level declines during infliximab treatment with no signifi-
cant differences between originator and biosimilar infliximab.
What is the translational message?
• Higher activation levels of PBMCs implies an ongoing systemic inflammation, pos-
sibly related to cardiovascular disease and obesity associated with psoriasis.
• Long-term infliximab treatment may be beneficial in preventing such comorbidi-
ties.
• Switching from originator to biosimilar infliximab does not seem to influence
intracellular signalling activity of PBMCs.
The pathogenesis of psoriasis encompasses interactions
between dendritic cells, T cells, keratinocytes and neu-
trophils.1–3 Cytokines released from these cells initiate and
perpetuate the inflammation that is characteristic of psoriasis.4
Patients have increased risk of cardiovascular disease and dia-
betes,5–7 indicating systemic inflammation. This is supported
by higher numbers of circulating lymphocytes8,9 and
increased gene expression of transcription factors and cytoki-
nes involved in differentiation of T helper (Th)1, Th17 and
Th22 cells.10,11 Furthermore, patients with psoriasis display
elevated levels of inflammatory cytokines in blood.12,13
Among the cytokines involved in psoriasis pathogenesis,
tumour necrosis factor (TNF)-a is regarded as one of the most
predominant.4 Levels of TNF-a are elevated in lesional psori-
atic skin and plasma, and peripheral blood mononuclear cells
(PBMCs) express high levels of TNF-a mRNA. Moreover,
patients with psoriatic arthritis have increased synovial TNF-
a.14 TNF-a signals via TNF-receptor 1 and 2, which are
expressed on all nucleated cells,14 and induces phosphoryla-
tion of nuclear factor kappa B (NF-jB), a transcription factor,
and p38 mitogen-activated protein kinase (MAPK). TNF-a sig-
nalling can result in phosphorylation of signal transducer and
activator of transcription 3 (STAT3), another transcription fac-
tor, and extracellular signal-regulated kinases (ERKs).15,16 NF-
jB regulates genes involved in inflammation, cell survival and
proliferation. It promotes expression of cytokines involved in
the pathogenesis of psoriasis, and NFKB1 and NFKBIL1 gene
variants are associated with severe psoriasis.17,18
The targets of STAT3 are mainly genes that are anti-apopto-
tic or pro-proliferative, or which regulate angiogenesis and
cytokine production.19 TNF-a induces activation of STAT3 via
phosphorylation of two of its residues, tyrosine (Y705) and
serine (S727).15,20 STAT3 is required for the development of
Th17 cells.21 Phospho flow cytometry has been used to show
that phosphorylation of STAT3 (at Y705) is increased in
regulatory T cells of patients with psoriasis, resulting in
impaired suppressive function.22 The Janus kinase–STAT path-
way is considered a promising drug target in psoriasis.23,24
Phosphorylated p38 MAPK can lead to activation of promoters
of genes involved in inflammation and production of inflam-
matory cytokines such as interleukin (IL)-6, IL-8 and IL-12.25
Fumaric acid esters, used in the treatment of psoriasis,
effectively inhibit the activity of p38 MAPK, decreasing pro-
inflammatory cytokine production.26 ERKs are MAPKs with
substrates that include transcription factors and immediate
early gene products involved in gene expression and cell func-
tion. Hyperactivity of this pathway is associated with unregu-
lated cell proliferation.27 Phosphorylation of the
abovementioned intracellular epitopes can be quantified by
phospho flow cytometry, potentially serving as a measure of
cytokine stimulation.28 Hence, this method can also gauge the
cytokine-blocking effect of biological drugs.
Biological drugs aimed at the cytokines TNF-a, IL-12/23
and IL-17A have revolutionized the treatment of psoriasis.29,30
Infliximab is a monoclonal antibody against TNF-a and CT-
P13 is a more recently licensed, cheaper biosimilar assumed
to have comparable efficacy and safety.31–33 However, despite
the same amino-acid sequence of the originator infliximab
and its biosimilar, differences in levels of afucosylated glycans
and binding affinity for FccRIIIa and FccRIIIb have been
detected, implying a potential difference in natural killer (NK)
cell activation.34 This might influence biological activity, toler-
ability and efficacy.35,36
The aim of the present study was to compare phospho-
rylation levels of intracellular epitopes in PBMCs from
patients with psoriasis treated with infliximab and healthy
controls using phospho flow cytometry, and to investigate
if switching from originator infliximab to biosimilar CT-
P13 affected clinical parameters and intracellular phosphory-
lation patterns.
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Materials and methods
Patient characteristics
In this observational study, at the Department of Dermatology,
Haukeland University Hospital, we included 25 patients with
psoriasis vulgaris who had all been diagnosed with severe pso-
riasis [Psoriasis Area and Severity Index (PASI) > 10] at an
earlier time point but were now in or close to remission (PASI
0–4) with frequent infusions of originator infliximab. In total,
22 patients were randomized either to continue infliximab or
to switch to the biosimilar CT-P13 as part of another study31
and therefore these samples were analysed double blinded.
The final three patients all continued on infliximab. Patients
gave written informed consent at the Department of Dermatol-
ogy, Helse Bergen (regional ethics committee approvals
2014/1373 and 2014/1489). There were 19 healthy controls
(age-, sex- and body mass index-matched, Table 1) included,
and samples were collected from the blood bank at the Hauke-
land University Hospital.
Blood sampling
Blood was collected at inclusion and after approximately 3
and 12 months, just before patients were to receive the next
infusion. The samples were collected between April 2015 and
September 2016 in lithium-heparin tubes (BD 367526, Becton
Dickinson Ltd., Reading, U.K.). PBMCs were isolated by den-
sity gradient centrifugation with Lymphoprep (Axis-Shield
Ltd, Dundee, Scotland) and cryopreserved in liquid nitrogen
until use, as described previously.37 Trough level and antidrug
antibodies were measured with immunofluorometric assay as
a routine analysis.37 The therapeutic range of the trough level
is above 2–3 mg L1.
Cell culture and stimulation
PBMC samples were thawed and rested in serum-free media (X-
vivo-20TM, Lonza, Basel, Switzerland) for 2 h at 37 °C, 5% CO2.
Cells were divided and either stimulated for 15 min with TNF-a
(50 ng mL1; Immunotools, Friesoythe, Germany) or left
unstimulated. Next, samples were fixed with 15%
paraformaldehyde (37 °C) incubated for 10 min at room tem-
perature and permeabilized with ice cold 100% methanol for
30 min on ice, as described previously.36,38 The cells were
washed with phosphate-buffered saline (PBS), then stained
according to a 4 9 2 fluorescence cell barcoding (FCB) grid
(three time points and one internal control with two stimulation
conditions) with different concentrations of Pacific Blue (100,
25, 63 and 0 ng mL1) and Pacific Orange (70 and
0 ng mL1; both Life Technologies, Grand Island, NY,
U.S.A.),40 then incubated in the dark at 4 °C. Further, cells were
washed and resuspended in fluorescence activated cell sorter
(FACS) buffer (PBS with 1% bovine serum albumin) before
combining the eight FCB combinations. FcR blocking reagent
(1 : 21) (Miltenyi Biotec, Bergisch Gladbach, Germany) was
added, cells were divided into two panels followed by staining
with titrated amounts of fluorochrome-conjugated antibodies
for 30 min in the dark at room temperature. Cells were then
washed with FACS buffer and resuspended in 200 lL FACS
buffer + 2 mmol L1 ethylenediamimetetraacetic acid.
Antibodies used for flow cytometry
The following monoclonal antibodies were used: PE conju-
gated anti-CD56 (clone N901, Beckmann Coulter, CA,
U.S.A.), BV786 conjugated anti-CD3 (clone SK7), Alexa Fluor
488 conjugated anti-CD20 [clone H1(FB1)], PE-Cy7 conju-
gated anti-NF-jB p65 (pS529, clone K10-8951250) and
Table 1 Characteristics of patients and healthy controls at inclusion
Originator infliximab CT-P13 Healthy controls
Sex, n
Women 2 3 3
Men 10 10 16
Age, years
Mean  SD 5083  1114 5153  1598 4732  1464
Range 28–65 29–79 24–70
BMI kg m2
Mean  SD 2767  462 2815  441 2627  391
Range 21–38 23–40 20–38
Duration of psoriasis, years
Mean  SD 2791  1055 2561  1015 NA
Range 11–49 8–38 NA
Psoriatic arthritis, n 5 3 NA
Duration of originator infliximab treatment before inclusion, months
Mean  SD 8683  3935 6892  4575 NA
Range 40–177 18–175 NA
NA, not applicable.
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anti-p38 (pT180/pY182, clone 36/p38), Alexa Fluor 647
conjugated anti-ERK1/2 [(pT202/pY204),20A,RUO –
612593] and anti-STAT3 (S727; clone 49/p-STAT3) and Per-
CP-Cy5.5 conjugated anti-STAT3 (Y705; clone 4/p-STAT3)
(all from BD Biosciences, San Jose, CA, U.S.A.).
Data acquisition
All samples from the same patient were stimulated, stained
and analysed under the same conditions on the same day. An
internal control, buffy coat from one healthy donor, was used
for every experiment, to account for interassay variation. All
the experiments were performed by one person within
2 weeks in July 2016 to minimize inter- and intra-assay varia-
tion in the laboratory and on the flow cytometer. Samples
were acquired on a LSRI Fortessa flow cytometer with
BDFACSDiVaTM Software (both BD Biosciences). The flow
cytometer was equipped with 407, 488, 561 and 635 nm
lasers. Further specifications are given in Table S1 (see Sup-
porting Information). A minimum of 200 000 events was
acquired in the intact cell gate. A representative gating strategy
is shown in Figure S1 (see Supporting Information).
Phosphorylation of NF-jB, ERK, p38, STAT3 (S727) and
STAT3 (Y705) were quantified in immune cell subsets. Beads
were used for compensation, which was performed in FlowJo
version 10.2. Cells within each subtype were analysed in Cyto-
bank40 in each stimulation condition. Basal phosphorylation
was defined as raw median fluorescence intensity (MFI) of the
inspected phosphoprotein in unstimulated cells, divided by
raw MFI of the corresponding phosphoprotein in unstimulated
internal control cells. The fold change was defined as raw MFI
of the inspected phosphoprotein in TNF-a-stimulated cells,
divided by raw MFI of the corresponding phosphoprotein in
unstimulated cells. The viability of the cells was above 98% in
the lymphocyte gate and 95% in the monocyte gate as deter-
mined by 7-aminoactinomycin D staining (data not shown).
Statistical analysis was carried out using SPSS Statistics 23/
24 (IBM, Armonk, NY, U.S.A.) with the Mann–Whitney U-test
for independent, unpaired data and the Wilcoxon signed-rank
test for paired data.
Results
In total, 12 of the 25 patients continued on the originator inflix-
imab and 13 switched to the biosimilar CT-P13. Duration of
psoriasis, incidence of psoriatic arthritis, dose of infliximab and
concomitant methotrexate were comparable between the two
treatment groups (Table 1). There were no significant differ-
ences between the groups regarding sex, age and body mass
index, PASI, Dermatology Life Quality Index (DLQI; Table 2) or
routine laboratory analysis at inclusion, after 3 and 12 months
(Table S2; see Supporting Information). One patient had anti-
drug antibodies at inclusion (originator infliximab group) and
no patients developed antidrug antibodies during the study.
Increased basal phosphorylation in peripheral blood
mononuclear cells from patients with psoriasis treated
with infliximab
The basal phosphorylation of NF-jB (S529), ERK1/2 (T202/
Y204), p38 (T180/Y182) and STAT3 (S727 and Y705) was
significantly higher in patients at inclusion than in the healthy
Table 2 Clinical parameters, treatment doses and intervals of the patients included in the study
Originator infliximab CT-P13
Inclusion 3 months 12 months Inclusion 3 months 12 months
Psoriasis Area and Severity Index
Mean  SD 136  069 102  088 120  099 228  111 168  122 138  083
Range 000–220 000–240 000–300 080–420 000–360 000–290
Dermatology Life Quality Index
Mean  SD 108  173 125  171 06  089 112  204 192  278 117  259
Range 0–5 0–6 0–3 0–6 0–10 0–9
Infliximab dose, mg
Mean  SD 590  104 590  104 590  104 638  296 638  296 638  296
Range 400–700 – – 300–1500 – –
Interval, weeks
Mean  SD 782  108 – – 654  113 – –
Range 6–10 – – 5–9 – –
Methotrexate mg
Mean  SD 1000  511 1000  511 1000  511 1438  544 1438  623 1438  623
Range 000–2000 000–2000 000–2000 750–25 750–25 750–25
Antidrug antibodies 1 1 1 – – –
Prior use of other biological, n
Adalimumab and etanercept 1 – – 0 – –
Adalimumab 1 – – 1 – –
Etanercept 2 – – 7 – –
Efalizumab 0 – – 1 – –
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controls in almost all cell populations analysed. Twelve
months after inclusion, patients still displayed significantly
higher basal phosphorylation levels than healthy controls, but
the number of epitopes with significant differences was
decreased (Fig. 1).
Further, we analysed phosphorylation patterns upon TNF-a
stimulation, relative to a corresponding unstimulated sample;
the fold change. As anticipated, because of the higher basal
phosphorylation levels at inclusion, the fold change of
pSTAT3 (Y705) upon stimulation was significantly lower in
monocytes and T, B and NK cells from patients at inclusion
compared with healthy controls. Fold changes of pERK in T
cells and pNF-jB in NK cells were also significantly lower
for patients than healthy controls. After 12 months, there
were fewer significant differences in fold change between
patients and healthy controls compared with at inclusion
(Fig. S2; see Supporting Information). Only fold changes of
pNF-jB in monocytes and NK cells in addition to pSTAT3 in



















































































































































































































































































































































































































































































































































































































Fig 1. Phosphorylation of intracellular epitopes in unstimulated peripheral blood mononuclear cells from the psoriasis and healthy control groups
at inclusion and after 12 months. Basal median fluorescence intensity (MFI) is shown as a ratio of raw MFI of unstimulated cells relative to raw
MFI of unstimulated internal control for phosphorylated nuclear factor kappa B (pNF-jB), phosphorylated extracellular signal-regulated kinase
(pERK), phosphorylated p38 (pp38), phosphorylated signal transducer and activator of transcription 3 (pSTAT3) (Y705) and pSTAT3 (S727). HC,
healthy control, green; Ps, patient with psoriasis, red. Each symbol represents one individual, the bar shows the median. NK, natural killer.
*P ≤ 005; **P ≤ 001; ***P ≤ 0001
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Patients treated with CT-P13 displayed similar basal
phosphorylation and fold change to those treated with
the originator infliximab after 3 and 12 months
Next, we compared phosphorylation levels in patients contin-
uing on the originator infliximab to those who switched to
CT-P13. The basal phosphorylation of NF-jB, ERK, p38 and
STAT3 (S727 and Y705) showed no significant differences at
inclusion, after 3 or 12 months. The only exception was
lower levels at inclusion of pSTAT3 (Y705) in NK cells
(Fig. S3a; see Supporting Information) and pSTAT3 (S727) in
CD3+ CD56+ cells (data not shown) from patients who con-
tinued treatment with the originator infliximab compared with
those who switched. Although no significant difference was
detected in basal phosphorylation, fold change of pSTAT3
(Y705) in B cells was significantly increased in patients on
CT-P13 relative to the originator infliximab 3 months after
switch (Fig. 2a, b). After 12 months, this difference was no
longer significant (Fig. 2c).
The phosphorylation of peripheral blood mononuclear
cells from patients with psoriasis on infliximab and CT-
P13 decreased during the study period
All patients were in clinical remission and treated with the
originator infliximab when included in the study. Neverthe-
less, when investigating the change of phosphorylation over
time separately for the originator infliximab and the biosimilar
CT-P13, there were significantly lower basal pSTAT3 (Y705)
levels in T, B and NK cells (Fig. 3a, Fig. S3a; see Supporting
Information) and pERK in all cell types 1 year after inclusion
in both treatment groups (Fig. 3b, Fig. S3b–f).
As the phosphorylation levels decreased over time for all epi-
topes except STAT3 (S727) (Figs 1 and 3), we questioned if
infliximab treatment length prior to inclusion had an effect. We
therefore analysed basal and stimulated pSTAT3 (Y705) levels
in T cells in relation to duration of infliximab treatment before
inclusion for individual patients in the two treatment groups.
No obvious correlation between the length of infliximab treat-
ment prior to inclusion and basal phosphorylation levels was
detected (Figs S4a, b, d and e; see Supporting Information). In
order to exclude ex vivo effects of the medication, drug trough
levels were compared with basal and TNF-a stimulated levels of
pSTAT3 (Y705) in T cells in both patient groups at three time
points. All patients had trough levels within the recommended
range, and trough levels did not correlate with phosphorylation
levels (Figs S4c and f, Table S2).
Discussion
To the best of our knowledge, phospho flow cytometry has
not been used previously on a broad panel of intracellular epi-
topes in PBMCs comparing patients with psoriasis and healthy
controls. Neither has it been used to monitor patients on bio-
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Fig 2. Significant difference in phosphorylation of signal transducer
and activator of transcription 3 (STAT3) (Y705) in B cells between
patients on infliximab and CT-P13 3 months after switch. (a) Fold
change of pSTAT3 (Y705) in immune cell subsets 3 months after
inclusion. (b) Basal median fluorescence intensity (MFI) ratio, TNF-a-
stimulated MFI ratio and fold change 3 months after inclusion. (c)
Basal MFI ratio, TNF-a-stimulated MFI ratio and fold change
12 months after inclusion. Basal MFI ratio: unstimulated sample/
unstimulated internal control. Stimulated-MFI ratio: TNF-a-stimulated
sample/unstimulated internal control. MFI fold change: TNF-a-
stimulated cells/corresponding unstimulated cells. IFX, originator
infliximab, blue; CT-P13, orange; IC, internal control. Each symbol
represents one individual, the bar shows the median *P ≤ 005
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originator to a biosimilar. Whereas there were significant dif-
ferences in intracellular phosphorylation of PBMCs between
patients with psoriasis and healthy controls, switching of
patients from the originator infliximab to the biosimilar CT-
P13 did not cause any major differences.
The basal phosphorylation levels in PBMCs from the psoria-
sis group were significantly increased in almost all analysed
phospho-epitopes and immune cell subsets at inclusion com-
pared with healthy controls, even though patients had been
treated with the originator infliximab for a minimum of
18 months and had no or low-grade skin inflammation. This
may indicate that systemic inflammation takes a longer time
to cease than skin lesions or that signalling through the inves-
tigated pathways is maintained, at least in blood, by cytokines
besides TNF-a. Basal levels of pSTAT3 (Y705) in patients with
psoriasis have been reported to be similar to those observed in
healthy volunteers.42 The discrepancy between these findings
and ours may be explained by different methodological
approaches (enzyme-linked immunosorbent assay was used in
the study by Punwani et al.42) and differences in patient char-
acteristics.
Our study would have benefitted from evaluation of phos-
phorylation levels and corresponding clinical parameters
before the patients started treatment. As the clinical effect was
sustained throughout the study period, PASI and DLQI were
of little value when interpreting how the phosphorylation
levels of PBMCs related to clinical parameters. Moreover, it

































































































































Fig 3. Basal phosphorylation over time for both patient groups, exemplified with T cells. (a) Phosphorylated signal transducer and activator of
transcription 3 (pSTAT3, Y705); (b) phosphorylated extracellular signal-regulated kinase (pERK); (c) phosphorylated nuclear factor kappa B (pNF-
jB); (d) phosphorylated p38 (pp38); (e) pSTAT3 (S727). The basal median fluorescence intensity (MFI) ratio is defined as raw MFI of measured
phosphoprotein in unstimulated sample cells relative to unstimulated internal control cells. IFX, originator infliximab, blue; CT-P13, orange; IC,
internal control. Each symbol represents one individual, the bar shows the median. *P ≤ 005, **P ≤ 001.
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healthy controls to evaluate normal variation over time. Most
of the patient samples at inclusion were collected almost a
year before the healthy controls samples, thereby increasing
duration of cryopreservation. At the same time, there was
broad interindividual variation for each time point regarding
duration of storage in liquid nitrogen without having an obvi-
ous effect on phosphorylation levels. Our findings of gradual
decreases in PBMC phosphorylation during treatment merit
further longitudinal studies including pretreatment samples.
In vitro inhibition of NF-jB or STAT3 (with parthenolide or
Stattic) blocks cytokine production by both Th1 and Th17
cells from patients with psoriasis. The same study also found
that infliximab reduced the number of Th1 and Th17 cells
in vivo.13 The psoriasis group in our study had increased pNF-
jB and pSTAT3 levels in addition to p38 and pERK in T cells
compared with healthy controls even though they were treated
with infliximab at inclusion. However, patients had a reduc-
tion of activated epitopes during the follow-up period. The
phosphorylation level of STAT3 (Y705) in T cells did not
seem to be influenced by drug trough level, most probably
because all of our patients had trough levels in or above the
recommended range. As infliximab treatment reduced levels of
pNF-jB and pSTAT3 in T cells over time, a gradual reduction
in Th1- and Th17-associated cytokines is plausible.
Our findings of elevated phosphorylation levels in distinct
immune cells support that systemic inflammation is increased
in psoriasis and may persist upon treatment even after resolu-
tion of skin manifestation. Systemic inflammation promotes
cardiovascular disease. The extent to which systemic treatment
reduces this risk is currently debated. Investigation of inflam-
mation in aortic and carotid arteries with positron emission
tomography revealed no differences after 16 weeks between
patients with psoriasis treated with TNF-a inhibitor adali-
mumab or placebo, and a small increase of inflammation in
the carotids after 1 year.43 Contrarily, another recent study
found decreased aortic inflammation in patients with severe
psoriasis who had at least 75% improvement of skin lesions
1 year after commencing biological drugs.44 In these studies
patients were treated differently, making it difficult to reach
conclusions. Our study supports the notion that use of sys-
temic rather than local treatment in patients with psoriasis at
risk of cardiovascular disease might be beneficial.
Comparing the two patient groups receiving the originator
infliximab or the biosimilar CT-P13, there were no significant
differences in basal phosphorylation after 3 and 12 months. Sur-
prisingly, fold change of pSTAT3 (Y705) in B cells was modestly
increased after 3 months in patients who switched to CT-P13
compared with those continuing on the originator infliximab.
However, no difference was detected after 12 months.
There was a notable tendency that basal- and TNF-a-stimu-
lated phosphorylation were decreased in more immune cell
subsets and epitopes in the CT-P13 group compared with the
originator infliximab group 3 and 12 months after inclusion.
This might reflect differences in the structure and effect of the
two drugs. Notably, this was not exclusively observed in NK
cells, which could have been predicted because of differences
in afucosylated glycans and affinity for FccRIIIa and FccRIIIb.
Studies with greater numbers of patients are needed to ascer-
tain potential differences in intracellular phosphorylation of
PBMCs between the two drugs.
Evaluation of immune-mediated diseases such as psoriasis
should ideally aim at the molecular aberrancy in each patient
for personalized treatment.45–49 To this end, assays capable of
predicting which treatments are most likely to be beneficial
for each individual are required, before commencing ther-
apy.50 Phospho flow cytometry may be a promising tool for
estimating systemic disease activity and treatment response of
people with psoriasis in the future51,52 and might be helpful
in the quest for new potential drug targets.53
In conclusion, relative to healthy controls, patients with
psoriasis displayed higher activation levels of PBMCs, and this
systemic inflammation decreased gradually with time on
infliximab treatment. Switching from infliximab to CT-P13
did not worsen clinical parameters or increase intracellular
phosphorylation of NF-jB, ERK, p38 or STAT3. Our data indi-
cate that phospho flow cytometry might represent a promising
tool for monitoring disease activity and treatment efficacy.
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Figure S1: Representative gating strategy used for the flow cytometry data. Intact cells 
were gated based on forward scatter area (FSC-A) and side scatter area (SSC-A) followed by 
single cell gating. The different samples were then identified through the intensities of their 
pacific blue (PB) and pacific orange (PO) stains. Cell subtypes were identified based on their 
FSC-A and SSC-A scatter properties as either monocytes or lymphocytes. Lymphocytes were 
then subtyped as B cells (CD20+), T cells (CD3+/CD56-), NK cells (CD3-/CD56+) or 































































































































































































































































































































































































































































































































































































































































































































































































































Figure S2: Fold change of intracellular epitopes in PBMC from healthy controls and 
psoriasis patients at inclusion and after 12 months. Fold change was defined as raw MFI 
of measured phosphoprotein in TNF stimulated cell subset relative to raw MFI of 
corresponding phosphoprotein in unstimulated cell subset. Immune cell subsets with 
corresponding pNF-κB, pERK, pp38, pSTAT3 (Y705) and pSTAT3 (S727) are shown. HC = 
healthy controls, green. Ps = psoriasis patients, red. Each symbol represents one individual, 
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Figure S3: Significant changes in basal phosphorylation of intracellular epitopes with 
time in both treatment groups. a: pSTAT3 (Y705) in T, B and NK cells at inclusion and 
after 12 months. b-f: pERK in immune cell subsets at inclusion, after 3 and 12 months 
follow-up. b: monocytes, c: T cells, d: B cells, e: NK cells, f: CD3+CD56+ cells. IFX= 










































































































































































































Figure S4: Basal MFI ratio and fold change for STAT3 (Y705) in T cells from 
originator infliximab (IFX) and CT-P13 patients compared to duration of 
treatment before inclusion and trough level.  a and d: Basal MFI and duration 
of IFX treatment before inclusion (months; shown at the right side of graph); a: 
IFX and d: CT-P13.  b and e: MFI fold change; b: IFX and e: CT-P13. c and f: 
Trough levels; c: IFX and f: CT-P13. Each patient represented by a single color 
and symbol. 
 
Table S1: Specifications of the LSRI Fortessa flow cytometer 
 
Fluorochrome  Emission filters 
PerCP-Cy5.5  LP: 685, BP: 695/40 
Alexa fluor-488 LP: 505, BP: 530/30 
PE-Cy7 LP: 750, BP: 780/60 
PE LP: −, BP: 582/15 
APC LP: −, BP: 670/14 
Pacific blue LP: −, BP:450/50 
Pacific orange LP: 570, BP: 585/42 
BV 786 LP: 750, BP: 780/60 
 
 
Table S2: Laboratory analysis: Laboratory values from patients at inclusion, 3 and 
12 months. 
 
Originator infliximab CT-P13 
 
Inclusion 3 months 12 months Inclusion 3 months 12 months 
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Abstract 
Psoriasis is a chronic immune-mediated skin disease accompanied by systemic inflammation and 
comorbidities. We analyzed peripheral blood mononuclear cells (PBMCs) in the search for immune 
signatures and biomarkers related to psoriasis severity and treatment effect. 32 patients with 
psoriasis and 10 matched healthy controls were included. PBMCs were collected before and after 
initiation of anti-TNF, anti-IL-17 or anti-IL-12/23 treatment and analyzed utilizing 26-parameter mass 
cytometry. The number of circulating Th17, Th22, Th9 and cytotoxic T cells were increased in severe 
psoriasis. Intracellular pp38 and pERK in T helper cells were associated with disease severity. 
Differences between responders and non-responders regarding cell composition and intracellular 
signaling were identifiable already at inclusion. Biological treatment induced memory cells, restored 
inhibitory PD-1 function of T cells and reduced a potential pro-atherogenic profile in monocytes. In 
conclusion, these results indicate amelioration of systemic inflammation in psoriasis after biological 
treatment. Such broad immune profiling may enable prospective stratification of patients regarding 
future treatment response. Successful early intervention may lead to a healthier trajectory with 
favorable implications on later comorbidities. 
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BMI Body Mass Index 
CAS Cell Acquisition Solution 
CCL20 Chemokine (C-C motif) ligand 20 
CCR4 (6, 10) C-C chemokine receptor type 4 (6, 10) 
CD Cluster of Differentiation 
CD8+ CD8 positive T cells 
CSB Cell Staining Buffer 
CVD Cardiovascular disease 
CXCL Chemokine (C-X-C motif) ligand 
CXCR3 Chemokine receptor type 3 
DC Dendritic cell 
DLQI Dermatological Life Quality Index 
ERK Extracellular signal–Regulated Kinases 
FC Fold Change 
FlowSOM Flow Self-Organizing Maps 
HC Healthy Controls 
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MSI Median Signal Intensity 
MST Minimum Spanning Tree 
MTX Methotrexate 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NK Natural Killer cell 
NKT Natural Killer T cell 
PASI Psoriasis Area and Severity Index 
PBMC Peripheral Blood Mononuclear Cell 
PBS Phosphate Buffered Saline 
PD-1 Programmed Death-1 receptor 
pSTAT Phosphorylated Signal Transducer and Activator of Transcription 
ROS Reactive oxygen species 
RT Room temperature 
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SPSS Statistical Package for the Social Sciences 
STAT Signal Transducer and Activator of Transcription 
Tbet T-box expressed in T cell 
Tc Cytotoxic T cell 
Th Helper T cell 
TNF Tumor Necrosis Factor 
Treg Regulatory T cell 
T1, T2, T3 Timepoint 1, 2, 3 
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Introduction 
Immunopathogenesis of psoriasis reaches beyond skin lesions [1-5]. Crosstalk between innate and 
adaptive immune system leads to self-sustaining inflammatory loops with keratinocytes, dendritic 
cells, T cells and the TNF/IL-23/IL-17 axis playing central roles [6-9]. Autoreactive cytotoxic T (Tc) 
cells and autoantibodies against LL37 are involved in initiation of plaques [7, 10, 11]. Th1 cells are 
recruited in initial phases, while Th17 and Th22 cells predominate in chronic plaques [6]. Epithelial 
Th22 and Tc17 cells constitute disease memory and the Th9 subset exert a role in induction and 
maintenance of inflammation [8, 12, 13]. Comorbidities including cardiovascular disease (CVD) share 
susceptibility genes and mechanistic links with psoriasis [3, 4, 14-16].  
Flow cytometry is traditionally used for phenotyping of peripheral blood mononuclear cells (PBMCs) 
but is limited by overlapping fluorescence spectra [17-19]. Increasing number of molecules are 
currently applied to define cell subsets. Mass cytometry has expanded detectable targets, facilitated 
broader characterization of immune cells, and given new insights to immunopathology of 
inflammatory diseases [20-25]. Extra- and intracellular molecules are labeled with heavy metal-
tagged antibodies before single cells travel through argon plasma, evaporating biological material, 
leaving only ions to be identified depending on time of flight as a function of atomic mass [20]. Since 
mass cytometry can be applied on blood and tissue, it is particularly advantageous in dermatological 
research [26]. 
Immunoprofiling enables individualized therapeutic strategies [27, 28]. Targeting systemic 
inflammation might alter the course of psoriasis with positive implications on comorbidities [14, 
29].The purpose of this study was to characterize PBMC subsets by use of mass cytometry, in the 
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Results 
Psoriasis and life quality improve with biological treatment 
At inclusion patients had severe psoriasis with reduced quality of life. Psoriasis Area and Severity 
Index (PASI) and Dermatological Life Quality Index (DLQI) were significantly improved at follow-up 
(Table S1). 15 of 32 patients reached PASI75 (responders), while the 17 non-responders improved 
moderately (< PASI75) (Table S2).  
 
Abundance of pathogenic PBMC subsets normalizes with biological treatment  
The frequency of Th2 cells was significantly lower at inclusion than at follow-up, and Th1 cells 
tended to decline to level of HC during treatment (Figure 1). The fraction of Th9 and Th22 cells was 
higher in patients at inclusion compared to 1-year follow-up (Figure 2). However, patients tended to 
have reduced levels of Tregs at inclusion and 4 months, but after 1 year the level had normalized.  
At inclusion, the number of Th cells expressing CD45RA was significantly higher and Th cell 
expressing CD45RO lower compared to follow-up time points (Figure S1). Further, patients at 
inclusion had a higher frequency of memory (CCR4+) CD8 positive cells (CD8+) than HC. Also, 
CD45RA+ CCR4low Tregs were more and CD45RO+ CCR4high Tregs less frequent at inclusion than at 
follow-up. The frequencies of classical and intermediate monocytes (MC) decreased during the first 
4 months of treatment but reached level of HC after 1 year (Figure S1). In order to exclude a possible 
influence of the BMI we investigated the different cell subset frequencies in the patients with the 
highest and the ones with lowest BMI at initiation. No typical patterns were seen. In addition, the 
BMI of the patients changed very little during the study in most of the patients (30/32). The 
remaining 2 had an increase of 7-10 units in BMI, and both showed an increase in Treg frequencies. 
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Expression of inhibitory PD-1 on T cells is influenced by biological treatment 
At inclusion, PD-1 expression on Th2 cells was higher and on CD8 cells lower in patients compared to 
HC (Figure S2). After 1 year, the expression of PD-1 on Th cells and Tregs in patients had increased.  
 
Intracellular phosphorylation of PBMCs normalizes during biological treatment 
At inclusion patients had higher intracellular phosphorylation of p38 in Th2 cells and Tregs, ERK in 
CD4 cells and STAT1 in classical MC than HC (Figure S3). The phosphorylation was still higher at both 
follow-up time points for Th2 cells and after 1 year for ERK in CD4 cells, implying improvement, but 
not complete normalization during biological treatment. Increased intracellular phosphorylation is 
exemplified with one patient at inclusion compared to one HC in Figure S4.  
 Basal intracellular phosphorylation of STAT1 and p38 decreased in classical MC from patients 
during the first 4 months of treatment and the level of pSTAT1 in Th17 cells was reduced after 1 year 
(Figure S5). 
 
Stratification of responders and non-responders 
Responders had a negative correlation between PASI improvement and FC of Th17 cell frequency 
after 4 months (T2/T1) (p ≤ 0.04, rho -0.535), and FC of CD8+ cells after 1 year (T3/T1) (p ≤ 0.04, rho -
0.545) (data not shown).  
Non-responders had a decrease of NK and NKT-like cells after 4 months relative to inclusion 
(Figure S6). Further, CD45RA/RO ratio in Tregs at inclusion was lower in responders compared to 
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non-responders. Responders had higher FC of PD-1 on CD4 cells after 4 months and on NK cells after 
1 year. 
 The expression of the epithelial-homing marker CCR10 on B cells was higher in patients than 
HC at inclusion (Figure S6). Interestingly, responders had higher FC of epithelial-homing CCR10 on 
Th, CD8+ and B cells after 4 months and on Th17 and NK cells after 1 year of treatment compared to 
non-responders (Figure 3).  
At inclusion non-responders had higher pSTAT1 in Th17 cells, pp38 in classical MC, and pp38 
and pNF-κB in intermediate MC than responders (Figure 4). Responders had higher FC of pNF-κB, 
pSTAT1 and pp38 in non-classical MC (increased activation) and lower FC of pSTAT3 in intermediate 
MC (reduced activation) compared to non-responders after 1 year (Figure S7). 
Discussion 
Exploiting mass cytometry, this study gives a novel, in-depth characterization of multiple blood 
immune cell subsets in psoriasis. The detected shift in Th1-Th2 balance and naïve/effector-memory 
predominance during treatment is in agreement with earlier reports [4, 7, 30-34]. The elevated 
levels of circulating Th9 and Th22 associated with active disease further supplements the current 
view on psoriasis pathogenesis. Increased level of CD8+ cells in active psoriasis, including memory 
CD8 (CCR4+) cells, is also confirmed by this study [24, 35-37]. Even though the Tc17 phenotype 
(CD8+CCR6+CD161+) is of pathogenic interest in psoriasis [7, 38-40], we did not detect significant 
differences between groups for this subset. However, reduction in CD8+ and Th17 subsets correlated 
with improvement of PASI. In light of the recently discovered autoantibodies against LL37, the higher 
expression of epithelial-homing CCR10 on B cells in psoriasis is especially interesting [10, 41]. The 
results also indicate that after response to biological treatment, there is a decline in recruitment of 
inflammatory cells to the skin.  
 
 
This article is protected by copyright. All rights reserved. 
10 
In psoriasis and coronary artery disease, Tregs are reduced in number with deficient 
suppressor activity. In psoriasis, this leads to insufficient peripheral tolerance against autoreactive T 
cells [15, 30, 42]. In addition, differentiation into IL-17 producing Tregs contribute to chronic 
inflammation [42-44]. At inclusion, our patients had a reduced fraction of Tregs, however, after 1 
year with biological treatment, the level was normalized. Interestingly, responders had relatively 
more memory than naive/effector Tregs initially than non-responders, implying that prospective 
stratification of treatment response might be possible. 
PD-1, a co-inhibitory molecule important for immune response silencing, is downregulated in 
psoriasis, resulting in immune overstimulation [45]. Blockade of PD-1 augments Th1 and Th17, but 
suppresses Th2 responses [46]. Our patients had reduced expression of PD-1 on CD8+ cells at 
inclusion, however, the opposite was detected for Th2 cells. After 1 year on biological therapy, the 
expression of PD-1 on Th cells and Tregs was increased. Further, responders had significantly larger 
increase of PD-1 on Th and NK cells at follow-up than non-responders. PD-1 constitutes a potential 
treatment target in psoriasis. 
Upon cell activation, intracellular molecules are phosphorylated to propagate signals [6, 47]. 
Patients with severe psoriasis had elevated levels of intracellular phosphorylation in Th2 cells and 
Tregs, in addition to classical monocytes. Further, intracellular phosphorylation was higher in CD4+ 
and Th2 cells after months on biological treatment, but with a decreasing trend. This reduction, but 
not complete normalization, might be related to genetic predisposition, underlining the chronicity of 
psoriasis [6, 12, 35, 48, 49]. Studies of inflammatory diseases have shown that phosphorylation in 
PBMCs decreases with treatment [24, 30, 50]. Interestingly, a recent study showed increased ROS 
production in activated memory CD4+ T cells [51]. Our patients had a significant reduction of 
phosphorylation in Th17 cells after 1 year. Further, we detected higher intracellular phosphorylation 
in Th17 cells, classical and intermediate monocytes from non-responders than responders at 
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inclusion, indicating that stratification based on immune-profile may predict future treatment 
response. 
Cardiovascular risk is linked to psoriasis by mechanistic pathways [15, 29, 52]. It is 
hypothesized that recirculating T cells lead to amplification of inflammation and contribute to 
comorbidities [13, 53]. Th1 and Th17 cells produce inflammatory mediators attracting monocytes, 
neutrophils and Tc cells [15]. Monocytes can be polarized towards pro-atherogenic phenotype by 
skin-inflammation, and recruitment to vessel walls is an early event in atherosclerosis [54, 55]. 
Elevated levels of classical and intermediate monocytes have been shown in CVD [56, 57]. Our 
psoriasis patients had a tendency of lower level of classical monocytes with higher intracellular 
phosphorylation than HC during the first 4 months of follow-up, possibly representing recruitment to 
vessel walls [58]. After 1 year, the frequency of classical monocytes was normalized. In addition, 
patients at inclusion had elevated levels of intermediate monocytes, which decreased during the 
first 4 months of treatment. 
Non-classical MC, however, have been postulated to exert an atheroprotective effect [58]. 
Responders had higher intracellular phosphorylation in non-classical MC after 1 year than non-
responders. The distribution of subtypes in the monocyte compartment indicates that systemic 
treatment of psoriasis may lower CVD risk [59]. 
This study is unique in exploring many PBMC subsets simultaneously in psoriasis, however, 
more markers could have been included. Antibodies sensitive to fixation were added before 
barcoding, increasing staining variability [60]. Live barcoding might interfere less with sensitive 
epitopes [61, 62]. Patients not naïve to biological treatment underwent recommended wash-out 
period before inclusion, however, some used MTX. Despite being the largest mass cytometry study 
on psoriasis, sample size was relatively limited. Because of the small groups of comorbidities and 
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different treatments given to individual patients, it was not possible to evaluate the effect of 
comorbidities or its treatment on the cell composition. 
Conclusions 
Mass cytometry enables a comprehensive description of systemic inflammatory cells and can be 
used for biomarker discovery linked to disease severity and treatment effect. This study 
simultaneously detects shifts in the balance and activation of PBMC subsets important for the 
pathogenesis of psoriasis and cardiovascular disease. Immune-profiling is a promising avenue for 
patient stratification and personalized treatment that may alter the chronic course of psoriasis with 
positive implications on comorbidities.  
 
Methods 
Characteristics of patients and healthy controls 
32 patients with severe psoriasis vulgaris were included at the Department of Dermatology, 
Haukeland University Hospital, Norway. They were prescribed infliximab (anti-TNF-α antibody), 
ustekinumab (anti-IL12/23 antibody), secukinumab (anti-IL17A antibody) or etanercept (TNF-
receptor blocker), eight in each group. Blood samples and clinical data were collected before 
initiation of biological therapy, after 4 and 12 months. 
10 age, sex and body mass index (BMI) matched healthy controls (HC) without psoriasis were 
included from the Blood bank at Haukeland University Hospital. The study was approved by the 
regional ethics committee (approvals 2014/1373 and 2014/1489). Written informed consent was 
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Blood sampling 
Blood was collected in Lithium-heparin tubes (Becton Dickinson Ltd., UK) and PBMCs were 
cryopreserved in liquid nitrogen following density gradient centrifugation as described previously 
[63]. The study encompassed 120 samples (96 patient samples, 18 HC samples and 6 internal control 
samples (IC)), divided on six 20-plex barcodes (BC). The ICs were PBMCs from the same donor and 
included in every BC. A schematic of the workflow is presented in Figure 5.  
 
Sample preparation and viability staining 
Cells were thawed and washed in serum-free medium X-VIVO-20TM (Lonza, Switzerland) containing 
endonuclease (PierceTM Universal Nuclease for Cell Lysis; Thermo Fisher Scientific, MA, USA), 
followed by resuspension in X-VIVO-20™ at room temperature (RT) before 120 min incubation (37°C, 
5% CO2). Equal number of cells from each sample was transferred to a MegaBlock® 96 deep well 
plate (Sarstedt, Germany). After centrifugation, cells were resuspended in RPMI-1640 (Lonza, 
Switzerland) before 5 min incubation, 37°C, with Cell-IDTM Cisplatin (Fluidigm, California, USA) at a 
final concentration of 2.5 μM.  
 
Antibody staining and barcoding 
Epitopes sensitive to fixation (CXCR3, CCR4, CCR6 and CD127) were stained on live cells. After wash 
with X-VIVO-20TM, cells were resuspended in Maxpar Cell Staining Buffer (CSB) containing FcR 
Blocking Reagent (Miltenyi Biotec, Germany) (2 μl per 1 million cells) and incubated 30 min on ice 
with Antibody Mix 1 (Table S4). Cells were washed twice with CSB followed by fixation with 1 ml Fix I 
Buffer from Fluidigm (10 min, RT). Barcoding was conducted in accordance with protocol for Cell-ID 
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20-Plex Pd Barcoding kit. The 20 samples were combined in a 5 ml Polystyrene Round-bottom Tube 
(BD Biosciences, MA, USA), and cells counted.  
For additional surface staining, 9 million barcoded cells were washed and resuspended in 
CSB followed by incubation with Antibody Mix 2 (Table S4) for 30 min (RT). After two washes and 10 
min rest on ice, permeabilization with ice-cold Methanol (Merck, Germany) was performed for 15 
min on ice. For intracellular staining, cells were washed twice resuspended in CSB, followed by 
incubation with Antibody Mix 3 (Table S4) for 30 min on ice. Between additional washes, the 
samples were fixed in 1.6% Formaldehyde solution (Methanol-free, Pierce™, diluted in PBS, RT, 10 
min). Samples were stored over night at 4°C in Cell-ID™ Intercalator–Ir diluted in Maxpar Fix and 
Perm buffer (final concentration 66.7 nM). 
The following day cells were centrifuged and washed prior to resuspension in Maxpar Cell 
Acquisition Solution (CAS), before final wash. Cells were left pelleted until acquisition. Unless 
otherwise stated, all products were from Fluidigm (California, USA) and washes done in CSB for 5 
min (453g/RT before, 800g/4°C after fixation). 
 
Mass cytometry acquisition, normalization and debarcoding 
Prior to acquisition, cells were suspended in 0.5 ml CAS solution with 1:10 concentration of EQ™ 
Four Element Calibration Beads. Samples were passed through a 35 µm cell-strainer (Falcon®, New 
York, USA) and analyzed on a Helios™ Mass Cytometer with WB injector (Fluidigm Corporation, 
California, USA). The resulting FCS files were normalized to beads (140Ce, 151Eu, 153Eu, 165Ho, 
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Gating, clustering and dimensionality reduction 
Clean-up gates for live single cells and elimination of beads were drawn in FlowJo 10.2 (Figure S9). 
Defining markers for identification of PBMC subpopulations [17-19, 22] are listed in Table 1. Manual 
gates were tailored per file and population according to gating strategy shown in Figure S10. In 
addition, FlowSOM analysis including 20.000 events (randomly subsampled) from each sample, was 
conducted [64]. Adjusted meta-clusters were tailored from FlowSOM clusters by use of Star plots 
and Minimum Spanning Tree (MST) and visualized after dimensionality reduction in Figure 6. 
 
Statistical analyses  
Wilcoxon and Mann-Whitney U test were conducted in SPSS v24. PASI75 was set as limit for 
responders (≥) and non-responders (<). Fold changes (FC) of Median Signal Intensity (MSI) at 
inclusion relative to corresponding IC was used to compare samples from different barcodes to 
overcome inter-assay differences. To compare individual variation over time, FC of follow-up 
samples relative to corresponding inclusion values were used. The relationship between PASI 
improvement and FC of marker expression was investigated with Spearman’s correlation coefficient. 
A p-value less than 0.05 was considered statistically significant. GraphPad Prism v8.0 and Cytobank 
Cellmass v7.0 were used for figures. 
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Table 1. Defining markers for identification of PBMC subpopulations. 
Population Defining markers 
T cells CD3+CD19- 
T helper cells CD3+CD19-CD4+CD8- 
CD8 positive cells CD3+CD19-CD4-CD8+ 
B cells CD19+CD3- 
Monocytes 
     -Classical 
     -Non-classical 



























Figure 1. Frequencies of Th1 and Th2 subsets in healthy controls (n=10) and psoriasis patients 
(n=32) at inclusion and follow-up during biological treatment. Percentage out of CD4 population is 
displayed. Box and whisker plots show quartiles with median, ends of whiskers represent min-max. 
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HC: healthy controls. PS-1: inclusion. PS-2: after 4 months and PS-3: after 1 year on biological 
therapy. Wilcoxon test was used to compare abundance of subsets of PBMCs at different time points 
for patients. Significant differences were defined as p ≤ 0.05.  
 
 
Figure 2. Frequencies of Th9, Th22 and Treg subsets in healthy controls (n=10) and psoriasis 
patients (n=32) at inclusion and follow-up during biological treatment. Percentage out of CD4 
population is displayed. Box and whisker plots show quartiles with median, ends of whiskers 
represent min-max. HC: healthy controls. PS-1: inclusion. PS-2: after 4 months and PS-3: after 1 year 
on biological therapy: PS-2 and after 1 year: PS-3. Wilcoxon test was used to compare abundance of 
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Figure 3. Change of CCR10 expression on PBMCs during biological treatment is compared for 
responders (R, n=15) and non-responders (NR, n=17). Box and whisker plots show quartiles with 
median, ends of whiskers represent min-max. Th: T helper cells. CD8+: CD8 positive cells. B: B cells. 
NK: Natural killer cells. T1: inclusion. T2: after 4 months and T3: after 1 year on biological therapy. 
Mann-Whitney test was used to compare expression on PBMCs for responders and non-responders. 
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Figure 4. Intracellular phosphorylation at inclusion in Th17 cells, classical and intermediate 
monocytes is compared for responders (R, n=15) and non-responders (NR, n=17) to biological 
treatment. Box and whisker plots show quartiles with median, ends of whiskers represent min-max. 
FC: Fold change. T1: inclusion. IC: internal control. Cl. MC: Classical monocytes. Itr. MC: Intermediate 
monocytes. Mann-Whitney test was used to compare expression on PBMCs for responders and non-
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Figure 5. Schematic representation of the workflow. PBMCs from 10 healthy controls and 32 
psoriasis patients before and after onset of biological therapy (4 and 12 months) were isolated and 
cryopreserved. Due to practical reasons, 20 samples were thawed together in six consequtive 
experiments, each including 19 PBMC samples (mix of patients and healthy controls) and one 
internal control. For each experiment, samples went through thawing, fixation, permeabilization, 
barcoding and staining with isotope-labeled antibodies. Acquisition was performed on a Helios mass 
cytometer, followed by normalization and debarcoding before data from all six experiments (120 
samples) were pooled. Identification of PBMC subsets from all 120 samples was done using the 
FlowSOM and viSNE algorithms. Finally, the median signalling intensities of extracellular and 
intracellular markers were analysed, comparing patients and healthy controls as well as the different 
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Figure 6. Clustering and dimensionality reduction methods used in analysis. a: Star plot generated 
from FlowSOM. Mean signal intensity of all clustering markers for cells in each cluster is shown. 
Height of tile corresponds to intensity. Clusters have relative size. b: Channel colored Minimum 
Spanning Tree displaying clusters from FlowSOM analysis, exemplified with CD4 expression on cells; 
red indicates high expression, and color specter down to blue indicates progressively lower 
expression. c: Colored cluster overlay showing the 13 tailored meta-clusters in FlowSOM based on 










Patients with severe psoriasis have alterations in peripheral immune cells that are restored 
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Table S1. Clinical data for patients (n=32): PASI and DLQI at inclusion, 4 and 12 
months after starting biological treatment, mean ± S.E. 
 PASI incl. PASI 4M PASI 12M DLQI incl. DLQI 4M DLQI 12M 
Infliximab 11.7 ±1.1 2.2 ±0.6 1.4 ±0.5 15.3 ±2.3 1.5 ±0.5 1.9 ±0.5 
Ustekinumab 11.1 ±3.4 4.3 ±1.8 2.9 ±1.1 10.0 ±2.2 3.1 ±0.8 2.5 ±0.8 
Secukinumab 8.0 ±1.8 1.9 ±0.5 1.9 ±0.4 13.3 ±3.1 4.6 ±1.8 4.1 ±2.0 
Etanercept 9.5 ±1.5 3.5 ±0.8 2.9 ±0.7 16.0 ±1.6 4.9 ±1.3 3.8 ±1.3 
All patients 10.1 2.0 3.0* 0.9 2.3* 0.7 13.7 2.3 3.5* 1.1 3.1* 1.2 
  *= p ≤ 0.001 
  4M= 4 months, 12M= 12 months 
 
 
Table S2. Improvement of PASI for non-responders (NR, n=17) and responders 
(R, n=15) after 4 and 12 months on biological therapy. Mean and min-max are 
listed. 
  % PASI improvement Min-max 
4 months NR 52 43-62 
R 90 84-95 
12 months  NR 57 46-67 
R 92 89-96 
 
 
Table S3. Characteristics of patients and controls: sex, age, weight, body mass 
index (BMI), psoriatic arthritis (PsA) and methotrexate (MTX) use; values are listed 
as min-max and mean. 
 
 Patients (n=32) Controls (n=10) 
Sex 24 ♂     8 ♀ 7 ♂     3 ♀ 
Age, years 18-74 (43)  29-58 (41) 
Weight, kg 61-133 (96) 65-122 (94) 
BMI 21-42 (30) 23-38 (30) 
PsA 13 0 




Table S4. Antibody panel for mass cytometry with target, antibody clone and 
conjugated metal listed. 
 Target Clone            Metal tag 
Antibody Mix 1 CCR4 L291H4 175Lu 
CXCR3 G025H7 163Dy 
CCR6 G034E3 141Pr 
CD127 A019D5 176Yb 
Antibody Mix 2 CD8a RPA-T8 146Nd 
CD19 HIB19 142Nd 
CD45RA HI100 143Nd 
CD45RO UCHL1 165Ho 
CD3 UCHT1 170Er 
CD4 RPA-T4 145Nd 
PD-1 EH12 2 H7 155Gd 
CD14 M5E2 160Gd 
CXCR5 RF8B2 171Yb 
CD25 2A3 169Tm 
ICOS C398.4A 151Eu 
CCR10 314305 164Dy 
CD161 HP-3G10 159Tb 
CD16 3G8 209Bi 
CD56 NCAM16.2 149Sm 
Antibody Mix 3 pNFkB K10x 166Er 
pp38 D3F9 156Gd 
pERK D1314.4E 167Er 
pSTAT1(Y701) 58DG 153Eu 
pSTAT3(Y705) 4/PStat3 158Gd 
pSTAT4 (Y693) 38/p-Stat4 174Yb 
pSTAT5 (Y694) 47 147Sm 
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Figure S1. Frequencies of immune cell subsets in healthy controls (n=10) and 
psoriasis patients (n=32) at inclusion and during biological treatment. a and b: 
Percentage of CD4 cells expressing CD45RA (a) and CD45RO (b). c: Frequency of 
memory CD8 (CCR4+) cells as % of PBMCs in healthy controls and psoriasis 
patients at inclusion. d: Treg expression of CD45RA and CD45RO in patients at 
inclusion and follow-up. e and f: Frequency of classical (e) and intermediate (f) 
monocytes (MC) in total PBMCs. Box and whisker plots show quartiles with median, 
ends of whiskers represent min-max. HC: healthy controls. Psoriasis patients at 
inclusion: PS-1, after 4 months on biological therapy: PS-2 and after 1 year: PS-3. 
   
 
  a                 b 











p  0.043 p  0.034














Figure S2. PD-1 expression on T cells. a: Differences between healthy controls 
(n=10) and psoriasis patients (n=32) regarding PD-1 expression on Th2 and CD8 
cells at inclusion. b: Change in PD-1 expression on CD4 cells and Tregs from 
patients at inclusion and after 1 year of biological treatment. Box and whisker plots 
show quartiles with median, ends of whiskers represent min-max. HC: healthy 
controls. PS-1: psoriasis patients at inclusion. PS-3: psoriasis patients at 12 months 
















































Figure S3. Comparison of intracellular phosphorylation in PBMCs from healthy 
controls (HC, n=10) and psoriasis patients (PS, n=32). Values are displayed as 
fold change (FC) of median signal intensity (MSI) from HC or PS normalized against 
MSI from corresponding internal control. a: pp38 in Th2 cells; b: pp38 in Treg cells; 
c: pERK in CD4 cells; d: pSTAT1 in classical monocytes. Box and whisker plots 
show quartiles with median, ends of whiskers represent min-max. Psoriasis patients 
at inclusion: PS-1, after 4 months on biological therapy: PS-2 and after 1 year: PS-3. 
 






Figure S4. Heatmap of basal level of intracellular phosphomarkers, exemplified 
with one healthy control (left) and one patient (right). Cl. Mc: classical 
monocytes. Ncl. Mc: non-classical monocytes. Tfh: T follicular helper cells.  












































Figure S5. Intracellular phosphorylation in PBMCs from psoriasis patients 
(n=32) during biological treatment. a: Phosphorylation of STAT1 and p38 in 
classical monocytes. b: Phosphorylation of STAT1 in Th17 cells. T1: inclusion. T2: 
after 4 months, and T3: after 1 year of biological therapy.  
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 CD4 (T2/T1)  NK (T3/T1)
FC
p  0.020 p  0.029















Figure S6. Frequencies of immune cell subsets in responders (n=15) and non-
responders (n=17) to biological therapy and of epithelial-homing B cells 
between healthy controls (n=10) and psoriasis patients (n=32). a: Fold change 
(FC) after 4 months of NK and NKT-like cell frequencies after 4 months in responders 
(R) and non-responders (NR). b: Ratio of CD45RA/RO expression in Tregs at 
inclusion for healthy controls (HC), R and NR. c: Change in PD-1 expression for R 
and NR displayed as FC for CD4 cells after 4 months and for NK cells after 1 year. d: 
Expression of CCR10 on B cells at inclusion for HC and patients. Box and whisker 
plots show quartiles with median, ends of whiskers represent min-max. T1: inclusion. 




Figure S7. Change in intracellular phosphorylation of monocytes after 1 year 
on biological treatment for responders (R, n=15) and non-responders (NR, 
n=17). a: Change in phosphorylation level of NF-κB, STAT1 and p38 in non-classical 
monocytes (Non-cl. MC). b: Change in phosphorylation level of STAT3 in 
intermediate monocytes (Interm. MC). Box and whisker plots show quartiles with 
















































Figure S8: Debarcoded samples showing event yield for each of the 120 
samples distributed on six barcodes. D1: day 1 of experiment, containing 20 
samples in the first barcode. D2: day 2 of experiment, containing the next 20 samples 








Figure S9: Example of clean-up gates made in FlowJo. The gates were tailored 
per file to identify live single cells 191Ir-193Ir (DNA1-DNA2); 191Ir-Event length; 























Figure S10: Representative gating strategy from FlowJo for cell populations 
identified by the panel consisting of 19 surface markers. Cl. Mc: classical 
monocytes, Itr. Mc: intermediate monocytes, Ncl. Mc: non-classical monocytes. Epith. 







unication Division, UiB  /  Print: Skipnes Kom
m
unikasjon AS
uib.no
ISBN: 9788230859766 (print)
9788230868935 (PDF)
